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Organophosphates (OPs), including nerve agents, target the cholinergic system
via inhibition of acetylcholinesterase (AChE), with subsequent overstimulation resulting
in neural damage and potential detrimental long-term effects. The efficacy of novel
pyridinium oxime reactivators, created with moieties to increase blood-brain barrier
penetration, was tested using highly relevant sarin and VX surrogates. Glial fibrillary
acidic protein (GFAP; an indicator of neural damage) and monoamines (dopamine,
serotonin, and their metabolites) were measured in select brain regions via
immunohistochemistry and HPLC, respectively. Adult male rats were treated ip with
high, sub-lethal doses of surrogates for sarin or VX, nitrophenyl isopropyl
methylphosphonate (NIMP) or nitrophenyl ethyl methylphosphonate (NEMP),
respectively. Surrogate treatment was followed after 1 hr by im administration of novel
oxime. Seizure activity was monitored, and kainic acid (KA) served as a positive control.
Administration of KA or surrogate (NIMP or NEMP) significantly increased GFAP
expression compared to control animals. Two different formulations of one particular
oxime (bromide vs. mesylate salt) attenuated seizures and reduced GFAP levels over

NIMP or NEMP treatments alone to levels near those of controls in both the piriform
cortex and dentate gyrus region of the hippocampus, while 2-PAM did not provide
protection. Serotonergic activity was increased in several brain regions, including the
piriform cortex, one hr after NIMP treatment. Markers of oxidative stress (isoprostanes)
were also tested. Overall, these results indicate the potential therapeutic efficacy of these
oximes and suggest this innovative chemistry may protect against neural damage induced
by OPs.
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CHAPTER I
INTRODUCTION

1.1

Historical Background of Nerve Agents:
The use of chemical weapons as warfare agents has a long history that dates back

centuries, but the organophosphate (OP) anticholinesterase nerve agents arose in the
1930’s in Germany. The OP compounds were first investigated and synthesized to be
used as pesticides, but their potential use in warfare was soon discovered. The OP nerve
agents inhibit the enzyme acetylcholinesterase (AChE) in the synapse of cholinergic
neurons. The incapacitation of this enzyme leads to an excess amount of the
neurotransmitter acetylcholine (ACh), which induces overstimulation of the cholinergic
system (Marrs, T. C. 1993; Kellar, K. J. 2006). The ultimate fate of an exposed
warfighter is respiratory failure and subsequent death.
Gerhard Schrader was the German chemist who discovered the first OP nerve
agent, tabun, in 1936 as he was working on the development of new insecticides for IG
Farben. Tabun was found to have a very high mammalian toxicity, and was easily
absorbed through the skin or by inhalation of the aerosol. These characteristics made
tabun too dangerous to be used as a pesticide, but the properties made it ideal as a
chemical warfare agent (CWA); consequently, Schrader was obligated by law to notify
the German military of his discovery. The military, enthusiastic about the potential
power of the new chemical agent, soon relocated Schrader to a secret military facility and
1

gave him the task of producing more tabun and developing additional nerve agents. An
OP of even higher lethality was soon discovered by the research team. This OP nerve
agent was named “sarin” in honor of the German chemist team (Schrader, Ambrose,
Rudriger, and van der Linde) credited for its discovery. Later Richard Kuhn and Konrad
Henkel developed “soman” at the Kaiser Wilhelm Institute for Medical Research in 1944
(Marrs, T. C., Maynard, R. L. et al. 2007; Gupta, R. C. 2009).
The class of nerve agents discovered in Germany became known as the “G”
agents. These specific compounds are abbreviated by the addition of a second letter used
to designate the specific chemical: GA (tabun), GB (sarin), GD (soman), and GF
(cyclosarin). These agents were stockpiled by the Germans, but they were never
employed during WWII. At the end of the war, the Allied forces split the discovered
nerve agents and continued to conduct research on these chemicals. The US began
making sarin in the early 1950s, and at this same time, a new series of OP nerve agents
was developed in England after a discovery by Ranajit Ghosh. This class of OPs was
given “V” as the first letter designation, and some of these chemicals that were produced
include the following: VE, VG, VM, and VX. The most widely produced of these nerve
agents was VX. During this same era, the US traded thermonuclear technology to obtain
the British VX technology, and subsequently, the US produced and stockpiled large
amounts of this chemical warfare agent. At the same time, therapeutic agents were also
being developed to combat these types of CWAs. Atropine, an antagonist of the ACh
receptor, was developed in the 1950’s. Also during this time period, oximes were first
used to reactivate AChE that had been inhibited by OPs (Gupta, R. C. 2009).
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In the 1960s, ethical concern of the use of CWAs became paramount;
consequently, stockpiles of chemical weapons were destroyed in the US during an
operation called CHASE, whereby the stockpiles were sunk into the sea. In the 1980’s,
the Iraqi military was thought to have used chemical weapons against Iran, with tabun
included as one of the chemical weapons possibly utilized. In 1990 during the first Gulf
War, chemical weapons were suspected to have been on the verge of deployment, but
were not reportedly implemented during the war. In 1984, Ronald Reagan initiated a ban
of chemical weapon use, and later in 1990 G.W. Bush and M. Gorbachev signed a treaty
banning the use and production of chemical weapons. Stockpiles were also to be
destroyed in the US and Soviet Union. The Chemical Weapons Convention (CWC) was
signed in 1993, initiated in 1997, and now most of the members of the UN have joined
allegiance. Also in 1997, the Organization for the Prohibition of Chemical Weapons
(OPCW) was established. The OPCW oversees the destruction of chemical weapon
stockpiles and monitors the chemical industry throughout the world to prevent the misuse
of chemicals. The stockpile destruction deadline for chemical weapons was April 29,
2012; however, the US and Russia are still working on the task. As of December 2008,
the US Army Chemical Materials Agency declared that 58% of the US unitary chemical
weapons (GA, GB, and VX) stockpile had been destroyed. The risk of CWA use by nonsignatories of the CWC is possible, and terrorist groups are also a major threat (Marrs, T.
C., Maynard, R. L. et al. 2007; Gupta, R. C. 2009).
Fear of retaliation has most likely prevented the use of chemical weapons during
recent conflicts, but a major concern today is the use of this type of weaponry by terrorist
organizations. Many chemical weapons are relatively easy to make and deploy. The
3

level of terror created by chemical weapon threats and/or use makes them an ideal choice
for terrorist activities. For example, the Japanese religious cult, Aum Shinrikyo, used
sarin during terrorist attacks at Matsumoto in 1994 and later in the Tokyo subway in 1995
(Yanagisawa, N., Morita, H. et al. 2006; Hoffman, A., Eisenkraft, A. et al. 2007). Here
19 people were killed and more than 6000 were injured in the attacks. After five years,
about 8% of the affected individuals experienced post-traumatic stress disorder (PTSD),
with additional psychological effects continuing in many individuals that were victim to
these terrorist episodes. These attacks made the use of nerve agents by terrorists real and
awoke the fear of future threats.
1.2

Nerve Agent Characteristics and Treatments:
Under normal physiological conditions, the cholinergic portion of the nervous

system serves an excitatory capacity throughout the body, with acetylcholine (ACh) as
the primary excitatory neurotransmitter at parasympathetic nerve endings. This
neurotransmitter is responsible for many processes such as muscular stimulation and
glandular secretion within the body. Acetylcholine is created on the presynaptic side of a
cholinergic synapse (cleft, or gap between neurons) when acetyl-CoA and choline are
combined by the enzyme choline acetyltransferase (ChAT). Excitation is evoked when
ACh is released into the neural synapse from the presynaptic membrane and binds to
receptors on the postsynaptic membrane; thereby, generating a postsynaptic signal when
an excitatory postsynaptic potential is reached (Hall, W. D. 1990). Under normal
conditions, the neurotransmitter is used and then quickly degraded and recycled. The
enzyme acetylcholinesterase (AChE) is responsible for rapidly converting ACh into the
inactive metabolites, choline and acetate, which are recycled within the presynaptic
4

terminal to synthesize more neurotransmitter. AChE is very abundant within the
cholinergic synapse and exhibits rapid kinetics, enabling this enzyme to quickly clear any
free ACh from the synaptic cleft, and prevent excess stimulation of cholinergic neurons
(Hall, W. D. 1990; Marrs, T. C. 1993).
The G-series nerve agents are all viscous liquids exhibiting varying degrees of
volatility, with sarin demonstrating the greatest vapor risk. Due to the volatility of these
agents, the most likely exposure routes are ocular, upper respiratory, and inhalation of the
vapor leading to systemic circulation. The route of exposure and dose will dictate the
symptoms evoked by the OP nerve agent. All of the nerve agents of this class are
anticholinesterase compounds, which inhibit acetylcholinesterase (AChE) via
phosphorylation and lead to the accumulation of excess acetylcholine (ACh) at neural
synapses and neuromuscular junctions. All organophosphates, including nerve agents,
inhibit AChE when the active serine site of the catalytic triad located in a gorge
(consisting of serine and adjacent histidine and glutamic acid) of AChE undergoes
nucleophilic attack of the OP, thereby phosphorylating the enzyme (Kesharwani, M. K.,
Ganguly, B. et al. 2010). The inhibited enzyme may further undergo an aging reaction
(dealkylation) that leads to the formation of a permanent alkyl-phosphate adduct that is
attached to the active serine. Consequently, this process renders the enzyme incapable of
reactivation by eliminating the possibility of dephosphorylation of the AChE. The aging
process happens very quickly for GD when bound to RBC-ChE, with the t1/2 of only 1.3
minutes. The times for aging of GA and GB are 46 and 5 hours, respectively (Gupta, R.
C. 2009). For successful recovery of the inhibited AChE, an antidote must be
administered before the aging process is too advanced. When AChE is inhibited by an
5

OP, the phosphorylated enzyme will recover very slowly when water hydrolyzes and
dephosphorylates the enzyme (spontaneous reactivation). Therapy is needed for most OP
poisoning, as spontaneous reactivation of the inhibited AChE is too slow to efficiently
reverse the effects of the OP.
With OP poisoning, the elevated levels of the neurotransmitter, ACh, affect the
peripheral and/or central nervous system by over-stimulation of muscarinic and/or
nicotinic ACh receptors (Kellar, K. J. 2006). Exposure to acutely toxic levels of a nerve
agent may lead to the following physiological changes: excessive ocular, bronchial,
salivary, and intestinal secretions; sweating; miosis (constriction of the pupil of the eye);
bronchospasm; increased intestinal motility; bradycardia; muscle fasciculation, weakness,
or paralysis; loss of consciousness; convulsions; depressed respiratory drive; and death
(Marrs, T. C., Maynard, R. L. et al. 2007). One of the most damaging effects of exposure
to a nerve agent is the injury induced by the induction of seizures/convulsions. Nerve
agent will cause prolonged epileptic seizures in an exposed individual, which will
produce substantial, irreversible, brain damage that, in turn, will result in long-term
deficits in cognitive function and behavior. In a study done by Kadar et al., an evaluation
was done on the acute and long-term neuropathology following exposure to a single LD50
dose of sarin in rats. Results of these experiments revealed about 70% of the animals
exhibited lesions of varying degrees of severity which were confined mainly to the
hippocampus, piriform cortex, and thalamus. Additionally, the damage was exacerbated
with time, as after three months, a significant reduction was found in the area of CA1 and
CA3 hippocampal cells (Kadar, T., Shapira, S. et al. 1995). In another study by
Lemercier et al., rats that were exposed to soman and exhibited repeated or prolonged
6

convulsions and survived showed neuronal changes that were described to resemble those
of hypoxic encephalopathy (Lemercier, G., Carpentier, P. et al. 1983). Neuronal
degeneration and necrosis was also found in rats treated with soman by McLeod et al.,
but only in the brains of animals that had experienced convulsions during the nerve agent
intoxication (McLeod, C. G., Jr., Singer, A. W. et al. 1984). Interestingly, in behavioral
experiments (open field, multiple T-maze, and tactile responsiveness) done by Raffaele et
al., abnormal brain pathology was greater in rats exposed to soman that performed poorly
in behavioral tests than rats which had received soman and were deemed normal in
behavioral tests (Raffaele, K., Hughey, D. et al. 1987). Prevention of these types of
deficits is still needed, as treatment with an anti-convulsant is not entirely protective
(Philippens, I. H., Melchers, B. P. et al. 1992).
The current chemotherapy for OP poisoning is atropine, an alkaloid that acts as an
antagonist of ACh muscarinic receptors, and pralidoxime (2-PAM), a reactivator of
inhibited AChE (Johnson, M. K., Vale, J. A. et al. 1992; Kuca, K., Cabal, J. et al. 2005).
In addition to atropine and oxime therapy, an anticonvulsant such as diazepam is often
given to help protect the CNS against seizures and neuropathological damage (Marrs, T.
C. 2004). Pretreatment with a carbamate has also been implemented during military field
scenarios where nerve agent exposure was likely to be encountered. The current
carbamate of choice is pyridostigmine bromide (PB), which binds to a fraction of AChE
and protects the enzyme from nerve agent exposure (Albuquerque, E. X., Pereira, E. F. et
al. 2006; Kassa, J. 2006). After a few hours, the PB moiety spontaneously hydrolyzes
from the AChE molecule and renders the enzyme physiologically functional again, and
this process thereby increases the effectiveness of atropine/oxime treatment (Wetherell,
7

J., Hall, T. et al. 2002). The current maximum period for pretreatment with PB is 21 days
(Gupta, R. C. 2009).
To be effective, reactivators, such as oximes, must act on the inhibited AChE
prior to the initiation of the aging process of the enzyme. Oxime reactivators are strong
nucleophiles that are effectively able to attack the phosphorylated (inhibited) AChE, and
remove the phosphorylating moiety from the AChE molecule (Jokanovic, M. and
Stojiljkovic, M. P. 2006). Reactivation occurs through nucleophilic attack by the anionic
–OH of the oxime on the phosphorus atom, splitting an oxime-phosphonate away from
the active site of the AChE. The liberated enzyme (AChE) now has a regenerated esteric
site on the enzyme that is again able to bind and cleave its normal substrate, ACh, thereby
rendering the enzyme functional again. Consequently, during this reactivation process
using oximes, oxime phosphates may be formed, and some of these molecules can also be
potent inhibitors (or re-inhibitors) of AChE, which can in turn be detrimental to the
recovery of inhibited AChE (Harvey, B., Scott, R. P. et al. 1986).
Pralidoxime is a well-tolerated and effective reactivator of AChE; however, it is
not very efficacious in the CNS because it does not penetrate the blood brain barrier
(BBB) very effectively and it is not effective against all tested nerve agents (Johnson, M.
K., Vale, J. A. et al. 1992; Kuca, K., Cabal, J. et al. 2005; Kassa, J. and Karasova, J.
2007). The BBB is the major obstacle to overcome when attempting to protect the CNS
from OP-induced damage using oximes (Lorke, D. E., Kalasz, H. et al. 2008). The BBB
consists of the interface between the walls of capillaries and brain tissue and its structure
includes tight junctions between neighboring capillary endothelial cells (Deli, M. A.,
Abraham, C. S. et al. 2005). This architecture contributes to the maintenance of ions and
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molecules at appropriate levels and also prevents toxic xenobiotics and endogenous
metabolites from entering brain, as molecules need to be lipophilic (non-polar) to enter
via diffusion into the cerebrospinal fluid (CSF). Specific transporters do exist that enable
certain molecules, such as glucose using the GLUT1 transporter (Simpson, I. A., Appel,
N. M. et al. 1999), to permeate the barrier. Another important transporter of the BBB is
p-glycoprotein, as this protein also functions as a very important transporter and
structural component of the BBB (Sharom, F. J. 2006; Sharom, F. J. 2011). This protein
is an ATP-dependent efflux pump that has broad substrate specificity and is an important
mechanism to extrude toxins and drugs, and may limit the entry of certain oximes, like 2PAM. Without affinity for a transporter, large and/or polar molecules (non-lipophilic)
can be introduced to the brain only by transiently disrupting the BBB with hyperosmotic
agents, such as with the sugar mannitol (Borlongan, C. V., Glover, L. E. et al. 2012).
The lack of effectiveness at protecting the CNS from OP toxicity using traditional
oximes drives research towards developing better oximes and therapies for treatment of
nerve agent poisoning (Stojiljkovic, M. P. and Jokanovic, M. 2006; Lorke, D. E.,
Nurulain, S. M. et al. 2008; Petroianu, G. A. and Lorke, D. E. 2008). Some promising
drugs include the oximes HI6, TMB-4, and obidoxime, but they are not equally effective
against all agents and types of exposure (Jun, D., Kuca, K. et al. 2005; Jokanovic, M. and
Stojiljkovic, M. P. 2006; Antonijevic, B. and Stojiljkovic, M. P. 2007). The overriding
limitation of the current treatment for OP poisoning is the inability to reactivate the
inhibited AChE in the brain. Oximes that have been used for medical countermeasures to
date are large, highly polar molecules (due to their quaternary structure and positive
charge) which cannot readily cross the BBB, and they are thus limited to reactivating
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AChE primarily in the PNS (Kellar, K. J. 2006). The lack of effectiveness in the CNS
leaves the brain vulnerable to excessive damage, and may lead to short and long-term
neuropathological deficits. In the short-term (while still on the field of battle), a soldier
exposed to a nerve agent and given the current treatment option may still be left in a state
that consists of altered brain neurochemistry such that he/she may be more vulnerable to
further assault, due to changes in cognitive ability. Long-term (weeks/months/years later
after exposure) changes to the brain, such as memory loss, are evidenced by the people
who were exposed to sarin during the terrorist attacks in Japan (Yanagisawa, N., Morita,
H. et al. 2006; Hoffman, A., Eisenkraft, A. et al. 2007; Yamasue, H., Abe, O. et al. 2007).
In a comparative study between victims that were treated for sarin exposure during the
1995 Tokyo subway attack and unaffected individuals, the volume of specific brain
regions (insular cortex, adjacent white matter, and the hippocampus) was found to be
smaller in the sarin exposed individuals (Yamasue, H., Abe, O. et al. 2007). Knowing
that long-term brain pathology is possible after exposure to OPs like nerve agents and
current treatment was utilized, a great need still exists for a compound capable of
entering the brain and rapidly dephosphorylating inhibited AChE before aging of the
enzyme occurs and before brain neurochemistry is adversely altered leading to long-term
neural damage.
1.3

Background Research at MSU
At Mississippi State University, research was funded through the Defense Threat

Reduction Agency (DTRA) to develop oximes (AChE reactivators) with greater potential
to cross the BBB than previously established oximes, such as 2-PAM. The goal was to
develop a novel oxime that may serve as an antidote for OP poisoning in the CNS, due to
10

the lack of central protection after exposure to OPs. Dr. Howard Chambers drove the
innovative creation of all of the oximes that were developed, and he incorporated
moieties that enhanced lipophilicities compared than the current oximes being used. This
characteristic will hopefully lead to enhanced reactivation of brain AChE following nerve
agent exposure because the incorporated lipophilic moieties should increase the
likelihood of crossing the BBB by offsetting the positive charge on the quaternary
ammonium of the oxime. The lipophilicities of the novel oximes were evaluated by
determining the n-octanol/water partition coefficients, and after determination, the value
was compared to that of 2-PAM (the currently used oxime for treatment against OP
poisoning in the US). This characteristic was then used to help guide the screening of
potential oximes for further testing in vitro.
In order to safely test the effectiveness of the novel oximes, unique OP
compounds were created and used as inhibitors against which the novel oximes were
tested for efficacy at reactivation of inhibited AChE. All of the surrogates utilized for
this project were also generated by Dr. Howard Chambers. Two sarin surrogates were
developed and were effectively used for in vitro and in vivo testing of the oximes. The
first sarin surrogate, used for the in vitro testing, was phthalimidyl isopropyl
methylphosphonate (PIMP). This compound is a non-volatile, potent AChE inhibitor that
is relatively safe to handle in a laboratory setting, and this OP phosphorylates (inhibits)
AChE via the same chemical moiety as sarin. The degradation of PIMP in aqueous
solution is about 15 minutes, a characteristic that allows inhibition to cease at this time
point and prevents further re-inhibition of AChE that may confound the in vitro results
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(Chambers, J. E., Chambers, H. W. et al. 2012; Meek, E. C., Chambers, H. W. et al.
2012).
Promising oximes that were tested in vitro against PIMP (at least 40-50%
reactivation of inhibited AChE) were then taken to the next tier of testing against the in
vivo sarin surrogate in a rat model, consisting of young, adult male Sprague Dawleyderived rats (obtained from Charles River Laboratories). The OP AChE inhibitor used
for the in vivo testing was 4-nitrophenyl isopropyl methylphosphonate (NIMP). This
nerve agent surrogate was invented and originally described by Ohta et al. (Ohta, H.,
Ohmori, T. et al. 2006); however, Dr. H. Chambers generated the surrogate to be used in
this project. Like PIMP, NIMP is also non-volatile, relatively safe to handle, and it also
inhibits AChE the same as the live nerve agent, sarin. But unlike PIMP, NIMP is more
stable in aqueous solution, thus making it ideal for in vivo experiments (Ohta, H.,
Ohmori, T. et al. 2006).
Additionally, the novel oximes were concurrently tested for reactivation of AChE
inhibited by a surrogate for VX. The OP created and used as the VX surrogate was 4nitrophenyl ethyl methylphosphonate (NEMP), and just as with the other surrogates, this
surrogate leaves AChE inhibited with the same moiety as the live nerve agent for which it
mimics (VX). NEMP has been used both for the in vitro screening of the oximes, as well
as for the in vivo testing in the rat model (Chambers, J. E., Chambers, H. W. et al. 2012;
Meek, E. C., Chambers, H. W. et al. 2012).
1.3.1

Background Related to Current Research
Many areas of the brain can be altered due to exposure to toxicants; however,

nerve agents (OPs) target/elicit effects in specific regions of the brain. The hippocampus,
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an area known to be involved in the memory process, is one of the areas known to be
affected by exposure to nerve agents (Shih, T. M. and McDonough, J. H., Jr. 1997).
Another area of the brain that is well-documented to be susceptible to damage induced by
nerve agents is the piriform cortex (Chapman, S., Kadar, T. et al. 2006; Myhrer, T.,
Enger, S. et al. 2010). These are also two of the primary brain regions that recent
research had evaluated for damage due to nerve agents, as was observed at many
presentations over the last few years at the national Society of Toxicology (SOT)
meetings. The amygdala, frontal cortex, and the striatum are also areas of the brain that
are involved in the propagation and spread of seizure activity (Myhrer, T., Enger, S. et al.
2007); consequently, these areas are also effected, as nerve agent exposure induces
seizures (Chapman, S., Kadar, T. et al. 2006; Aroniadou-Anderjaska, V., Figueiredo, T.
H. et al. 2009).
Excessive expression of GFAP is indicative of astrocytic activation, whereby
changes in the level of GFAP give an indication if structural damage is occurring and if
an inflammatory response has been initiated due to OP exposure (Schmued, L. C.,
Stowers, C. C. et al. 2005; Otani, N., Nawashiro, H. et al. 2006). GFAP is a type III
intermediate filament that is located in astrocytes in the brain, and this protein is involved
with interactions between astrocytes and neurons. Neuronal injury or inflammation
induces cellular signaling in astrocytes to increase the expression of this protein which
can lead to astrogliosis and may result in glial scarring (Chen, Z., Duan, R. S. et al. 2005;
Collombet, J. M., Four, E. et al. 2007). Chemicals known to increase the expression of
GFAP from astrocytes include lipopolysaccharide (LPS) and kainic acid (Milenkovic, I.,
Nedeljkovic, N. et al. 2005; Ifuku, M., Katafuchi, T. et al. 2012). Evidence also shows
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that the increased expression of GFAP by astrocytes may be induced by nitric oxide (NO)
through the guanylate cyclase (GC)-cGMP activated protein kinase (PKG) signaling
pathway (Brahmachari, S., Fung, Y. K. et al. 2006). Consequently, elevated levels of
GFAP are linked to neural damage and conditions of potential neurodegeneration
(Benkovic, S. A., O'Callaghan, J. P. et al. 2006).
Kainic acid was originally isolated from certain species of seaweed and
prototypically induces epileptic-type seizures that can lead to neurodegeneration
(Routbort, M. J., Bausch, S. B. et al. 1999; Otani, N., Nawashiro, H. et al. 2006). This
chemical is a specific agonist of the kainate receptor typically activated by the
neurotransmitter glutamate; consequently, overstimulation of the glutamatergic system
occurs, leading to epileptiform-type seizures and neural damage similar to nerve agents
(Hopkins, K. J., Wang, G. et al. 2000; Riljak, V., Milotova, M. et al. 2007). Prime target
areas for the initiation and spread of seizures are in the piriform cortex and hippocampus
(Myhrer, T., Enger, S. et al. 2007). Seizure activity for 30 minutes in duration has been
shown to cause severe damage to the hippocampus, piriform cortex and some thalamic
nuclei in rats exposed to sarin (Chapman, S., Kadar, T. et al. 2006).
Other neural systems are also affected by nerve agents, such as the serotonergic
and dopaminergic systems, based on previous research on nerve agent effects in the brain
(Coudray-Lucas, C., Le Guen, A. et al. 1987; Fosbraey, P., Wetherell, J. R. et al. 1990;
Christin, D., Daulon, S. et al. 2008). For example, research has indicated increased
serotonergic turnover in the brain after injection with sub-lethal amounts of nerve agents
or OPs (paraoxon, DFP, soman, sarin, and tabun), in animals also exhibiting signs of
seizures (Prioux-Guyonneau, M., Coudray-Lucas, C. et al. 1982; Fernando, J. C.,
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Hoskins, B. H. et al. 1984). It has also been shown that excessive cholinergic and
glutamatergic stimulation may lead to alterations of the dopaminergic and serotonergic
systems. In vitro, ACh has been shown to stimulate the release of DA in rat striatal tissue
and tissue from the caudate nucleus of cats (Giorguieff, M. F., Le Floc'h, M. L. et al.
1976). Glutamate and kainic acid have also been shown to induce the release of DA from
the caudate putamen of rat slices (Clow, D. W. and Jhamandas, K. 1989). Changes to
these neural systems may be informative as to the behavioral/physiological effects that
are exhibited after exposure to an OP, such as nerve agents.
Behavioral effects from organophosphate poisoning may be transient or persistent
and include impaired vigilance and reduced concentration, slowed processing of
information and psychomotor speed, memory deficit, linguistic disturbance, depression,
and anxiety and irritability (Levin, H. S. and Rodnitzky, R. L. 1976). In a recent study,
mice exposed to sarin and psychological stressors exhibited behavioral and endocrine
changes that were manifested by excessive grooming and an enlargement of the adrenal
glands in conjunction with a reduction in catecholamines (Mach, M., Grubbs, R. D. et al.
2008). Overall, a better understanding of changes to this type of neurochemistry may
provide further insight toward how a soldier may be affected in the field of battle when
nerve agents are utilized or how civilians may be impacted by OP exposure due to
terrorist activities, such as the terrorist attacks in Japan.
Evidence also exists that acute exposure to OPs will generate reactive oxygen
species (ROS) as well as excessive stimulation of glutamatergic neurons. The
overstimulation of both the cholinergic and glutamatergic neuronal systems in
conjunction with the generation of ROS may also lead to detrimental neuronal damage
15

(Milatovic, D., Gupta, R. C. et al. 2006). Two biomarkers to evaluate ROS in the brain
are F2-isoprostanes (F2-isoPs) and F4-neuroprostanes (F4-NeuroPs), which are oxidative
damage products of arachidonic acid (AA) and docosahexaenoic acid (DHA),
respectively (Milatovic, D., Montine, T. J. et al. 2011). The F2-isoPs are found
ubiquitously in the brain, while the F4-NeuroPs are localized to neuronal membranes.
These markers have been successfully used to evaluate oxidative damage due to OPs, as
is evidenced by the work of Milatovic and Aschner at Vanderbilt University using
diisopropylphosphorofluoridate (DFP) in a SD rat model (Zaja-Milatovic, S., Gupta, R.
C. et al. 2009). Here, elevation of both F2-isoPs and F4-NeuroPs began by 30 minutes
after a single injection (1.25 mg/kg, sc) of DFP, with peak levels reached at 60 minutes,
and were still significantly elevated at 2 hours, but returned to control levels by 6 hours.
Brain AChE was also inhibited by 90% at 30 minutes, and was sustained at 60 minutes.
By 2 hours, AChE was still inhibited by 86%, with levels dropping to 83% by 6 hours.
Dendritic damage was also observed in the pyramidal neurons in the CA1 region of the
hippocampus in animals sacrificed 1 hour post-injection with the OP. Pretreatment with
antioxidants (vitamin E (α-tocopherol), N-tert-butyl-α-phenynitrone (PBN), and
memantine HCl (MEM)) were found to protect from the oxidative damage (ZajaMilatovic, S., Gupta, R. C. et al. 2009). This same group of researchers also found the
same type of oxidative damage in the brains of mice treated with kainic acid (icv
injection), also indicated by increases in levels of both F2-isoPs and F4-NeuroPs (ZajaMilatovic, S., Gupta, R. C. et al. 2008).
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1.3.2

Overall Research Summary
The main objective of the research described here was to characterize the effects

of both the sarin and VX surrogates (NIMP and NEMP, respectively) in vivo by
evaluating changes to the brain structure/physiology. This research was done in addition
to gathering in vitro and in vivo data on the reactivation potential of the novel oximes as
they were developed by Dr. H. Chambers. In particular, the in vivo reactivation data
from individual animals was informative as to how effective the OP had inhibited the
AChE in the animal at the time of sacrifice and aided in the interpretation of data that was
generated on other neurophysiological changes that occurred. One of the particular
interests of this research was investigating pathological changes that may be occurring in
the CNS due to exposure to the nerve agent surrogates. Research was done to investigate
how the brain neurochemistry and structure was altered from exposure to NIMP and
NEMP. The overall hypothesis of this research was that the surrogates would induce
physiological changes in the brain, and would result in neural damage. Intervention with
novel oximes (of good reactivation potential), capable of entering the brain in
physiologically relevant amounts, was hypothesized to be protective from these putative
changes/damage. The most efficacious oxime that had been tested to date in vivo against
the nerve agent surrogates was oxime20, and this oxime was utilized to test the above
hypothesis.
The bulk of Chapter Two describes the experiments that evaluated the levels of
glial fibrillary acidic protein (GFAP) in rat brain sections taken from selected areas of the
brain (dentate gyrus of the hippocampus and the piriform cortex) known to be affected by
OPs. The amygdala, frontal cortex, and the striatum are also areas of the brain that are
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involved in the propagation and spread of seizure activity (Myhrer, T., Enger, S. et al.
2007); consequently, these areas are also affected, as nerve agent exposure induces
seizures (Chapman, S., Kadar, T. et al. 2006; Aroniadou-Anderjaska, V., Figueiredo, T.
H. et al. 2009). Seizure activity was also likely induced by the nerve agent surrogates in
these areas; however, GFAP activity was not evaluated here. These brain regions that
may show the early neural damage, however, were focused on in addition to the
hippocampus and piriform cortex when evaluating for neurochemical changes in the
brain (Chapter Three).
Glial fibrillary acidic protein (GFAP) was the marker used to detect
neuroinflammation/potential for neurodegeneration and was used to indicate brain areas
that were likely damaged due to exposure from the OP surrogates. The technique
employed to evaluate brain GFAP levels was immunohistochemistry (IHC), whereby the
secondary antibody was luminescent, making detection of the protein easy to observe and
measure. This method allowed for the comparison of luminosity intensity between
treatment groups to evaluate the relative differences in GFAP expression. Here, both the
sarin (NIMP) and VX (NEMP) surrogates were evaluated for changes in GFAP
expression, with kainic acid (KA) used for comparison as a positive control, as this
chemical has been shown to cause elevated expression of GFAP (Schmued, L. C.,
Stowers, C. C. et al. 2005). Additionally, the best oxime that had been generated to date
(oxime20) was tested for efficacy at protecting from OP-induced elevations in the GFAP
expression and the ability to attenuate seizures.
Chapter Three details the research that was done to evaluate monoaminergic
changes (serotonergic and dopaminergic systems) in the brain of rats exposed to NIMP,
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NEMP, novel oximes, and the combinations. Brain punches were collected from various
brain regions, including the hippocampus (dentate gyrus), piriform cortex, prefrontal
cortex, striatum, amygdala, and substantia nigra and analyzed for the levels of
monoamines using HPLC with electrochemical detection. These types of analyses can
provide insight into changes to several neurotransmitter systems in the brain that could be
affected by nerve agents. Additionally, it was thought that the changes to these systems
may be informative as to the behavioral/physiological effects that are exhibited after
exposure to an OP. Overall, a better understanding of changes to this type of
neurochemistry may provide further insight toward how a person may be affected in the
field of battle when nerve agents are utilized or how civilians may be impacted by OP
exposure due to terrorist activities, such as those that occurred in 1994 and 1995 in Japan.
Chapter Four describes the experiments attempted to characterize oxidative
damage induced by the novel nerve agent surrogate NIMP by evaluating the levels F2isoPs in the brain, based on the data of the time frames (30min, 60min, 2hr, and 6hr after
OP injection) used by the research team at Vanderbilt University. The level of AChE
inhibition was very similar in amount and duration to what is documented with the nerve
agent surrogates here at MSU. The initial experiment was conducted by looking first at
the one hour post OP (NIMP) treatment, which corresponds to the peak isoprostane levels
found by the other group using DFP. Eventually with later experiments, oxime 20
(oxime used with GFAP and neurochemistry experiments; and most effective reactivator
of AChE) would be given to some of the animals alone and in conjunction with the
surrogate to test its effect on the levels of isoprostanes.
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CHAPTER II
NEURAL IMPACT OF NERVE AGENT SURROGATES

2.1

Introduction
The threat of exposure to organophosphate (OP) nerve agents exists for both

military populations and civilians who might be exposed through terrorist activities
(Hoffman, A., Eisenkraft, A. et al. 2007); however, a fully protective means of treatment
for exposure still does not exist. Exposure to OP’s, such as certain pesticides and nerve
agents, causes inhibition of the enzyme acetylcholinesterase (AChE); consequently,
excess excitatory neurotransmitter acetylcholine (ACh) is present throughout the
synapses and neuromuscular junctions of the cholinergic system (Marrs, T. C. 1993).
The severity of symptoms is determined by the degree of overstimulation of the
cholinergic system and is dictated by the amount and duration of OP exposure. Current
treatment utilizes an oxime, such as 2-PAM, to reactivate inhibited AChE and atropine
sulfate to block muscarinic ACh receptors (Marrs, T. C., Maynard, R. L. et al. 2007). An
anticonvulsant, such as diazepam, can also be used to help control seizures in cases where
AChE inhibition is high (Marrs, T. C. 2004). This approach can effectively save lives by
protecting the peripheral nervous system; however, traditional oximes like 2-PAM
(Johnson, M. K., Vale, J. A. et al. 1992; Lorke, D. E., Nurulain, S. M. et al. 2008) cannot
effectively cross the blood-brain-barrier (BBB)(Persidsky, Y., Ramirez, S. H. et al.
2006). The brain is furthermore left vulnerable to detrimental long-term neural damage,
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which may cause behavioral alterations and neurological and cognitive deficits, as was
seen in victims of the Tokyo subway terrorist attacks (Yanagisawa, N., Morita, H. et al.
2006; Hoffman, A., Eisenkraft, A. et al. 2007; Yamasue, H., Abe, O. et al. 2007).
The lack of protection to the brain drives the approach of this research program
with the overall goal to develop an oxime that can cross the BBB, and that is still able to
quickly reactivate inhibited AChE in appreciable amounts in the brain, therefore,
reducing the potential for neurological damage. Our ultimate strategy employed in vivo
testing of novel pyridinium oximes that were synthesized by Dr. Howard Chambers with
unique chemistries that make them more lipophilic than 2-PAM. The efficacy testing of
the novel oximes was done using highly relevant nerve agent surrogates created for sarin
(4-nitrophenyl isopropyl methylphosphonate; NIMP) and VX (4-nitrophenyl
ethylphosphonate; NEMP)(Chambers, J. E., Chambers, H. W. et al. 2012; Meek, E. C.,
Chambers, H. W. et al. 2012)(Appendix Fig. 1). Initial testing of the oximes (structures
located in Appendix Fig. 2 and Table 1) was comprised of an in vitro screening technique
to characterize the AChE reactivation potential and an additional assay to determine the
lipophilicity of the novel oxime. The data gathered from both of these assays drove the
decision to take a particular oxime to the next tier of testing, the in vivo efficacy test in a
Sprague Dawley derived rat model.
With the overall goal of our research to try to protect the brain from neurological
damage due to exposure to an OP, we chose to use glial fibrillary acidic protein (GFAP)
as a marker to measure neural damage in the brain. GFAP is a type III intermediate
filament that is found in astrocytes in the brain, and this protein is involved with
interactions between astrocytes and neurons. Neuronal injury or inflammation induces
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cellular signaling in astrocytes to increase the expression of this protein; consequently,
high levels of this protein can lead to astrogliosis and may result in glial scarring (Chen,
Z., Duan, R. S. et al. 2005; Collombet, J. M., Four, E. et al. 2007). Furthermore, elevated
levels of GFAP are linked to neural damage and conditions of potential
neurodegeneration (Benkovic, S. A., O'Callaghan, J. P. et al. 2006). After rats were
exposed to nerve agent surrogates, elevated expression of GFAP was used as a marker to
indicate neurological damage in the brain (Otani, N., Nawashiro, H. et al. 2006).
Likewise, lack of overexpression of this protein in animals treated with surrogate in
conjunction with novel oxime indicated a protective effect of the oxime from OP
exposure. Additionally, in vivo administration of kainic acid (KA) served as a positive
control, both for seizure activity and neurological damage, as KA induces similar seizure
activity as the surrogates and causes elevated expression of GFAP (Milenkovic, I.,
Nedeljkovic, N. et al. 2005; Schmued, L. C., Stowers, C. C. et al. 2005). The origin of
KA is from marine seaweed and this chemical is a specific agonist of the kainate
receptor, which is endogenously stimulated by glutamate. This chemical causes
overstimulation of the glutamatergic system and induces epileptic-type seizures and
neural damage similar to the effects of nerve agents (Hopkins, K. J., Wang, G. et al.
2000; Riljak, V., Milotova, M. et al. 2007).
The hippocampus, an area known to be involved in the memory process, is an
area likely to be affected by exposure to the nerve agent surrogates (Lee, H. K., Choi, S.
S. et al. 2004; Otani, N., Nawashiro, H. et al. 2006). Other areas of interest include the
piriform cortex, amygdala, frontal cortex, and the striatum. These are all areas of the
brain that are involved in the propagation and spread of seizure activity, which is
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characteristically induced by nerve agents (Chapman, S., Kadar, T. et al. 2006), and are
regions that may show the earliest neural damage. However, an evaluation of neural
damage due to the OP’s was only evaluated in the dentate gyrus region of the
hippocampus and in the piriform cortex. Only these two regions were chosen because
both have been documented as damaged due to nerve agents (Myhrer, T., Enger, S. et al.
2007; Myhrer, T., Enger, S. et al. 2010) and our positive control, kainic acid (Djebaili,
M., Lerner-Natoli, M. et al. 2001; Riljak, V., Milotova, M. et al. 2007) and expensive
antibodies could be conserved by limiting the number of areas evaluated. The most
effective oxime from the in vivo efficacy studies (best brain reactivation of inhibited
AChE) was further evaluated for neural protective capabilities (tested in two different
formulations; bromide and mesylate salts; structures in Appendix Fig. 1). The mesylate
salt version of oxime20 was generated by Southwest Research Institute and tested in
addition to the original bromide version of oxime20 because the mesylate may have
better druggability (i.e., solubility, bioavailability, and shelf-life). These properties
would make the mesylate formulation better suitable for therapeutic application in the
pharmaceutical market. Protection attributed by the novel oxime from potential
neurodegeneration was evidenced by a reduction in the GFAP expression, as compared to
nerve agent surrogates. The data from these experiments are presented in this chapter.
2.2
2.2.1

Methods
In vitro screening of the oximes:
Much of the initial screening of the oximes (against PIMP) was performed by

Ashley Harmon as her thesis research for her Master’s degree. Since then, several
members of Dr. Janice Chambers’ lab, including myself, have been responsible for
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gathering the in vitro reactivation data, using several different OP’s. The following is an
overview of the general procedure that was developed. Screening of the novel oximes for
reactivation efficacy consisted of first inhibiting AChE in rat brain tissue by incubating
with a nerve agent surrogate, followed by addition of the oxime to reactivate AChE. In
summary, pooled (n=4-5) whole brain tissue from naïve rats was homogenized at
40mg/ml in 0.05 M Tris-HCl buffer (pH 7.4 at 25ºC) with a Wheaton tissue grinder. To
inhibit brain AChE, the brain homogenate was incubated at 37ºC in a shaking water bath
with PIMP (175nM) or NEMP (56nM) for 15 minutes, which inhibited approximately
80% of AChE. For the reactivation phase, novel oxime (100μM final concentration) was
added to the mixture and incubated for an additional 30 minutes. After this time, the
tissue was diluted to 1mg/ml, and then assayed for AChE activity. The inhibition of
AChE by the nerve agent surrogates (OPs) and reactivation by the novel oxime were
calculated by comparing to the solvent/OP controls. Ethanol was the OP vehicle, and a
50:50 mixture of dimethylsulfoxide and ethanol was used as the oxime vehicle.
2.2.2

Spectrophotometric determination of brain AChE activity:
All of the incubations for the assay were performed at 37ºC in a shaking water

bath. The blanks were first inhibited of all cholinesterase activity by adding 1mM (final
concentration) eserine sulfate and incubating for 15 minutes. The addition of eserine also
corrected for any color that may be generated from any non-AChE processes. Next,
1mM acetylthiocholine (ATCh; final concentration) was added as the substrate, and the
reaction was terminated after 15 minutes (and yellow color developed) by adding a
mixture of 0.05% sodium dodecyl sulfate (SDS) and 5,5’-dithio-bis (nitrobenzoic acid;
DTNB) 2.6mM (Ellman, G. L., Courtney, K. D. et al. 1961; Chambers, J. E. and
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Chambers, H. W. 1989). The mixture was transferred to cuvettes and the absorbance was
then measured at 412nm using a spectrophotometer.
2.2.3

N-Octanol/Water Partition Coefficients:
The determination of lipophilicity of the novel oximes was conducted by

members of Dr. Howard Chambers’ laboratory, with a few assays also performed by staff
of Dr. Janice Chambers. Lipophilicity was determined by measuring the partitioning of
the oxime between water and n-octanol, calculated as the Kow (concentration in
octanol/concentration in water).
2.2.4

In vivo testing of the oximes and dosage of animals for downstream brain
analyses:
Oximes that were able to reactivate approximately 50% or more of the inhibited

AChE in the in vitro assay were taken to the next tier of testing, consisting of in vivo
administration of the oxime using young, adult male Sprague Dawley rats (obtained from
Charles River Laboratories). Rats were given a single ip injection of the selected nerve
agent surrogate (NIMP, 0.325mg/kg; NEMP, 0.4mg/kg both in DMSO and injected at
1ml/kg body weight), which induced seizures and inhibited approximately 80% of the
brain AChE after 1 hour (Chambers, J. E., Chambers, H. W. et al. 2012; Meek, E. C.,
Chambers, H. W. et al. 2012). This time point yielded peak inhibition, and at this time an
im injection of oxime (100µmoles/kg in DMSO injected at 0.5ml/kg body weight) was
administered. The mesylate formulation of oxime20 is abbreviated as “OxMS” in this
research, and OxMS was administered at the same molar equivalent and by the same
method as the bromide version (oxime20), except 0.9% saline was used as the vehicle for
solubility. Animals were continually monitored for seizure activity, and later were
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sacrificed 30 and 120 minutes post-oxime injection, with the brain rapidly dissected from
the skull and collected upon sacrifice. Half of each brain was homogenized at 40mg/ml
in Tris buffer and AChE activity was determined. Protein concentration was also
determined for all tissue samples using the Folin phenol reagent (Lowry, O. H.,
Rosebrough, N. J. et al. 1951). The inhibition of AChE by the OP and reactivation by the
oxime were calculated by comparing to the animal controls (vehicle only, and OP only).
The same dosage amounts of OP and oxime were also used in animals analyzed
for neural damage in the brain; however, longer time points were used to allow for a time
course analysis of physiological/structural damage induced by the nerve agent surrogates.
Characterizing the OP-induced neural damage, as evidenced by GFAP
immunohistochemical staining, was done by analyzing damage 2, 4, or 7 days post -OP
treatment.
Additional rats treated ip with kainic acid (10mg/kg in 0.9% saline, injected at
2ml/kg body weight) were used as positive control animals to verify seizure-induced
neural damage and to establish a benchmark for GFAP expression (Schmued, L. C.,
Stowers, C. C. et al. 2005). Animals were monitored for seizure activity and sacrificed 2
and 4 days post-injection with kainic acid, and the brains processed for neural damage
using GFAP as an indicator of neurodegeneration.
Shipping costs of the rats from Charles River Laboratories increased substantially
towards the end of the experiments for this project; consequently, a cohort of rats of the
same strain (Sprague Dawley) was obtained from Harlan Laboratories for comparison
purposes, as Harlan became a more cost effective source of rats. Physiological
parameters of the Harlan rats, such as levels of brain AChE inhibition after treatment
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with nerve agent surrogate, were tested and compared to those of the rats used throughout
this study from Charles River. Additionally, Harlan rats were evaluated for GFAP
expression after administration of NIMP alone and in conjunction with oxime20 to
further compare the physiology of the rats supplied by the different vendors. Dosing of
these animals was performed the same way as was done for previous experiments.
2.2.5

Immunohistochemistry:
Brains from rats treated with OP (NIMP or NEMP), oxime, OP/oxime, or vehicle

control were collected, and immediately rinsed with ice cold saline and cut in half
sagittally. The left half of the brain was snap frozen in liquid nitrogen, and was later
utilized to determine AChE activity. The right brain half was hand-dissected into two
regions (one containing striatum/piriform cortex, and the other containing the
hippocampus/amygdala) and placed into 10% neutral buffered formalin for 3 days at 4°C
to fix the tissue. The formalin was then removed and a 25% sucrose solution in
phosphate buffered saline (PBS) was added, as a cryoprotectant of the brain tissue. The
sucrose solution was removed after the tissue sections had equilibrated with the sucrose
solution (2-3 days) and the brain sections were frozen by immersion into a beaker of
isopentane on dry ice. The cryoprotected tissue was then stored at -80°C until sectioning.
The staining protocol was modified from an existing published protocol (Forster,
G. L., Pringle, R. B. et al. 2008; Pringle, R. B., Mouw, N. J. et al. 2008). The brains were
sectioned at 25μm using a Leica cryostat set at -10°C, with each collected slice placed
into a well of a 24-well plate (kept on ice) containing 0.01M PBS, and then stained for
GFAP expression. The sections were first incubated in a 3% blocking solution of goat
serum in 0.01M PBS for 2 hours at room temperature (22°C) on a horizontal
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shaker/rocker. The blocking solution was removed and control or primary antibody
solution (1:1000 GFAP; Chemicon AB5804) was then added and incubated overnight on
a rocker at 4°C. The sections were rinsed 3 times (separated by 10 min) in diluent, and
then a fluorescent secondary antibody (1:800 Dylight 488; Thermo-Fisher) was added
and the slices were incubated at 22°C for another 2 hours (plates were kept in dark, as the
secondary antibody is light sensitive). The sections were then washed 3 times in diluent,
and mounted using a free floating technique to glass slides that had been treated with
poly-L-lysine to promote adherence. An additional step was performed on some slices to
verify cell nucleus location. These sections were incubated in 4',6-diamidino-2phenylindole (DAPI; fluorescent DNA stain; blue) solution on the slide for 10 minutes,
and then rinsed 3 times in PBS. The slides were then cover-slipped, and stored at 4°C
until imaged for GFAP luminosity.
Images were taken using an Olympus BX51 microscope with appropriate
fluorescent filters and an integrated camera. Pictures were taken of the dentate gyrus and
piriform cortex regions of the brain using the 20X objective on the microscope. The
saved images were then analyzed for GFAP expression using the ImageJ software
(available from NIH). The background was subtracted from the images and a region of
interest (ROI) was set at a fixed size. The ROI was randomly overlaid on cells that were
exhibiting expression of GFAP, and the levels of luminosity were determined and
depicted as integrated density. These values were used to quantify the GFAP expression
levels of each of the samples.
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2.2.6

Statistical Analyses:
Significant differences in the in vivo AChE activity data (comparing the 30 min

and 2 hr time points) were analyzed using t-test analysis (Sigmastat Software), with
P<0.05 indicating significant differences between the groups analyzed.
For the GFAP data, one-way analysis of variance (ANOVA) was used to test
differences between treatment groups, with P<0.05 indicating significant differences
(SigmaStat Software). Tukey’s post hoc test was used when treatment groups were found
to be significantly different from one another. Three to four animals were used for each
treatment group, and 30 regions of interest (ROI; ten from three different slices) were
collected from each animal during imaging.
2.3

Results
Many of the novel oximes were able to reactivate AChE inhibited by the nerve

agent surrogates appreciably well when tested in vitro (see Table 2.1; also see Appendix
for relevant structures). Additionally, all of the oximes that have been synthesized are
more lipophilic than 2-PAM (also shown in Table 2.1). Oxime20 is also highlighted
(blue) in Table 2.1 for comparison purposes, as this oxime was also the best reactivator in
vivo of inhibited brain AChE, and was the oxime also tested for neural protection from
the OP’s.
For the in vivo experiments, both NIMP (0.325mg/kg) and NEMP (0.4mg/kg)
were effective AChE inhibitors, with peak inhibition (80% of brain AChE) occurring 1
hour post ip injection with the nerve agent surrogates. Seizure activity commenced
within 15-20 minutes after injection and consisted of classic signs of OP intoxication:
both fore and hind limb muscular shaking/rigidity, head bobbing, and were accompanied
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by salivation/lacrimation. Sixteen of the oximes tested in vivo have shown efficacy at
reactivating brain AChE inhibited by the surrogates, with oxime20 showing the best
potential (Fig. 2.1). All of these oximes showed some reactivation potential, unlike 2PAM. Additionally, a significant (P<0.05) elevation in reactivation of brain AChE was
found between the 30 minute and 2 hour time points (post administration of novel oxime)
for a few of the novel oximes (oximes 13, 33, and 45) tested in vivo (Fig. 2.1). When
administered (im injection; 100 µmol/kg) at peak AChE inhibition, both formulations
(bromide and mesylate salt) of the lead oxime (oxime20) were equally capable of
reactivating appreciable levels of AChE inhibited by the sarin and VX surrogates in the
brain. At 30 minutes, 25% of inhibited AChE had been reactivated, and by 2 hours, the
level of reactivation increased to 35%, and these values were not significantly different
between surrogates (NIMP vs. NEMP; Fig. 2.2). For comparison, treatment with the
traditional oxime, 2-PAM, yielded no reactivation in the brain. Additionally, seizure
activity was attenuated in animals treated with both formulations of the lead oxime.
Animals treated with kainic acid displayed similar patterns of seizure activity, and after 2
and 4 days, GFAP expression was significantly (P<0.001) elevated compared to control
animals in the piriform cortex (Fig. 2.3). Expression of GFAP was also significantly
(p<0.05) elevated in kainic acid treated animals compared to controls at 2 days in the
dentate gyrus region of the hippocampus; however, data were not generated at 4 days.
Administration of the VX surrogate, NEMP, significantly (p<0.001) increased GFAP
expression in the piriform cortex compared to controls at 2 and 7 days after treatment
(Fig. 2.4). After 4 days treatment, both nerve agent surrogates (NIMP and NEMP)
showed significantly (p<0.05) elevated GFAP, and surrogate+oxime20 treatment reduced
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GFAP expression to near control levels in both the piriform cortex and the dentate gyrus
region of the hippocampus (Figs. 2.5 and 2.6). This same pattern of reduced GFAP
expression was also found using the mesylate salt formulation of oxime20 in both brain
regions (Fig. 2.7). The expression of GFAP was unchanged in both the piriform cortex
and the dentate gyrus after 4 days in animals treated with NIMP vs. NIMP+2-PAM (Fig.
2.8). Additionally, the overall pattern of reduced GFAP expression after treatment with
surrogate+oxime20 compared to surrogate alone was also seen using animals from a
different supplier; Charles River vs. Harlan (Fig. 2.9).
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Table 2.1

Summary of in vitro data generated on oximes that were taken to the next
tier of testing, the in vivo rat model.
% Rat Brain
Reactivation

Oxime

Relative
Potency

*PIMP (sarin surrogate)

% Rat Brain
Reactivation

Relative
Potency

*NEMP (VX surrogate)

Lipophilicity

Relative
Lipophilicity

**P Oct/H2O

2‐PAM

91%

1.00

88%

1.00

0.006

1.00

TMB‐4

98%

1.08

80%

0.91

<0.001

0.20

Oxime 1

54%

0.59

52%

0.59

0.128

21.3

Oxime 6

65%

0.71

67%

0.76

0.184

30.7

Oxime 13

65%

0.71

57%

0.65

0.138

23.0

Oxime 20

53%

0.58

47%

0.53

0.352

58.7

Oxime 21

72%

0.79

76%

0.86

0.172

28.7

Oxime 29

71%

0.78

74%

0.84

0.489

81.6

Oxime 30

38%

0.42

48%

0.55

0.259

43.2

Oxime 32

59%

0.65

61%

0.69

0.017

2.8

Oxime 33

55%

0.60

62%

0.70

0.183

30.5

Oxime 36

52%

0.57

58%

0.66

0.465

77.5

Oxime 37

51%

0.56

45%

0.51

0.015

2.5

Oxime 38

54%

0.59

61%

0.69

0.298

49.7

Oxime 39

38%

0.42

37%

0.42

0.094

15.7

Oxime 45

80%

0.87

70%

0.80

0.015

2.5

Oxime 47

51%

0.56

62%

0.70

0.061

10.2

Oxime 48

57%

0.63

67%

0.76

0.112

18.7

Relative potency and lipophilicity are compared to 2-PAM (2-PAM is set at 1.0, and
oximes are compared to this). TMB-4 was also included, as it is another potent AChE
reactivator in the peripheral nervous system. All oximes were able to reactivate AChE
inhibited by the OPs in vitro in rat brain homogenate (40mg/ml). All oximes were also
more lipophilic than 2-PAM. Oxime20 is highlighted in blue, as this oxime was also the
best reactivator in vivo and was used to evaluate GFAP expression and neurochemistry.
(Special notes: *30-min incubation with 100µM oxime following 15-min incubation
with nerve agent surrogates, PIMP or NEMP; n=3 replications; **P Octanol/water
partition coefficient). See Appendix Figs. 1 and 2 and Appendix Table 1 for relevant
nerve agent, surrogate, and oxime structures.
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Figure 2.1

In Vivo Rat Brain AChE Reactivation Following Oxime Treatment

In vivo reactivation of NIMP inhibited rat brain AChE following treatment with novel
oximes (n=3-4). Rats were given a single ip injection of the nerve agent surrogate, NIMP
(0.325mg/kg), which induced seizures and inhibited approximately 80% of the brain
AChE after 1 hour. At this time of peak inhibition, novel oxime was administered im
(100µmoles/kg), and rats were sacrificed 30 minutes and 2 hours post-oxime
administration and brains assayed for AChE activity. Sixteen oximes are represented that
demonstrated efficacy to reactivate AChE in the rat brain. A significant (P<0.05)
elevation in reactivation of brain AChE was found between the 30 minute and 2 hour
time points for oximes 13, 33, and 45. Note: No level of reactivation was exhibited by
2-PAM in the brain.
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Figure 2.2

AChE Reactivation in Rat Brain

Comparison of in vivo reactivation of rat brain acetylcholinesterase (AChE) after
treatment with OP surrogates (NIMP and NEMP) and novel oxime 20 (n=3-4). Rats
were given a single ip injection of the nerve agent surrogates NIMP (0.325mg/kg) or
NEMP (0.4mg/kg), which induced seizures and inhibited approximately 80% of the brain
AChE after 1 hour. At this time of peak inhibition, novel oxime20 was administered im
(100µmoles/kg), and rats were sacrificed 30 minutes and 2 hours post-oxime
administration and brains assayed for AChE activity. The level or AChE reactivation by
oxime20 against both surrogates was nearly identical for both time points (P>0.05).
Note: No level of reactivation was seen for 2-PAM.
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Figure 2.3

GFAP: Piriform Cortex and Kainic Acid

Levels of glial fibrillary acidic protein (GFAP) 2 and 4 days after treatment with the
positive control kainic acid (KA; 10mg/kg, ip) were significantly elevated compared to
controls in the piriform cortex (*P<0.001; n=3-4). Representative images are shown for
each group: (Control, 2-Day Kainic Acid, 4-Day Kainic Acid). Seizure activity was also
documented in these animals, and the activity observed in surrogate treated animals was
consistent when compared to animals treated with the positive control, kainic acid.
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Figure 2.4

GFAP: Piriform Cortex and NEMP

Levels of glial fibrillary acidic protein (GFAP) 2 and 7 days after treatment with the VX
surrogate, NEMP (0.4mg/kg, ip), were significantly elevated compared to controls (*p<0.
001; n=3-4). Representative images are shown for each group: Control, 2-Day NEMP, 7Day NEMP.
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Figure 2.5

GFAP: 4-Day Treatment

Levels of glial fibrillary acidic protein (GFAP) 4 days after treatment with NIMP
(0.325mg/kg) and NEMP (0.4mg/kg) were significantly elevated (*p<0.05; n=3-4)
compared to control, Oxime 20, and surrogate+Ox20 animals. Representative images are
shown for each group.
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Figure 2.6

GFAP: 4-Day Treatment

Levels of glial fibrillary acidic protein (GFAP) 4 days after treatment with NEMP
(0.4mg/kg) were significantly higher (*p<0.05; n=3-4) compared to control, Oxime 20,
and NEMP+Ox20 animals in both the piriform cortex and the dentate gyrus region of the
hippocampus. Note: The data for the piriform cortex is repeated from Fig. 2.5 and is
also shown here as a comparison to the dentate gyrus region.
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Figure 2.7

GFAP: 4-Day Treatment

Levels of glial fibrillary acidic protein (GFAP) 4 days after treatment with NIMP
(0.325mg/kg) or NEMP (0.4mg/kg) were significantly higher (*p<0.05; n=3-4) compared
to control, Oxime MS, and respective surrogate+OxMS animals in both the piriform
cortex and the dentate gyrus region of hippocampus. Note: OxMS is the mesylate salt
formulation of oxime 20.

Figure 2.8

GFAP: 4-Day Treatment

Levels of glial fibrillary acidic protein (GFAP) 4 days after treatment with NIMP
(0.325mg/kg, ip) or NIMP+2PAM were significantly higher (*p<0.05; n=3-4) compared
to control and 2-PAM treated animals, both in the piriform cortex and the dentate gyrus
region of the hippocampus.
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Figure 2.9

GFAP: 4-Day Treatment, Harlan Rats

Levels of glial fibrillary acidic protein (GFAP) 4 days after treatment with NIMP
(0.325mg/kg) were significantly higher (*p<0.05; n=3-4) compared to control, Oxime 20,
and NIMP+Ox20 animals in Sprague Dawley-derived rats supplied from two different
vendors (Harlan vs. Charles River) in both the piriform cortex and the dentate gyrus
region of the hippocampus.
2.4

Discussion
Both nerve agent surrogates (NIMP and NEMP) were effective inhibitors of brain

AChE, and the seizure activity displayed was similar to that induced by kainic acid. The
levels of inhibition of brain AChE after exposure to the nerve agent surrogates was
similar to levels obtained by other researchers using live nerve agents, as well as other
surrogates for nerve agents. For example, Milatovic et al. observed similar seizure
activity and levels of AChE inhibition using diisopropylphosphorofluoridate (DFP) in
rats as was detected using the surrogates in this research (Zaja-Milatovic, S., Gupta, R. C.
et al. 2009).
Higher expression of GFAP indicates the activation of astrocytes, the potential for
neural structural damage occurring at a later time, resulting in neurodegeneration. Both
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surrogates as well as kainic acid were found to elevate GFAP levels in the same brain
regions, the piriform cortex and the hippocampus, as regions known to be involved in the
propagation and spread of seizures (Aroniadou-Anderjaska, V., Figueiredo, T. H. et al.
2009; Myhrer, T., Enger, S. et al. 2010). These data are consistent with the findings of
Schumed et al., where both of these brain regions in mice exhibited neural degeneration
after treatment with kainic acid, as evidenced by significantly higher levels of GFAP and
positive staining for Fluoro-Jade C (Schmued, L. C., Stowers, C. C. et al. 2005).
Extensive damage was also seen by Riljak et al. in the dentate gyrus region of the
hippocampus of rats treated with kainic acid, consistent with our data (Riljak, V.,
Milotova, M. et al. 2007). Also, in studies by Damodaran et al. evaluating global
changes in gene expression after exposure to sarin in Sprague Dawley rats, the gene for
GFAP was found to be elevated after exposure to the nerve agent in several brain regions
within 1-2 hours and persisted for at least 7 days (Damodaran, T. V., Bilska, M. A. et al.
2002; Damodaran, T. V., Greenfield, S. T. et al. 2006). These data are also consistent
with the changes that were observed in this research using GFAP as a marker for neural
damage.
Animals that were treated with surrogate+oxime20 (either the bromide or
mesylate salt formulation) showed protection against potential neural damage, as
indicated by lower GFAP expression compared to surrogate alone treated animals.
Importantly, seizure activity also diminished soon after the administration of oxime20,
indicating a therapeutic advantage of this oxime. Additionally, no protection was
provided by the traditional oxime 2-PAM, as evidenced by no GFAP expression
difference between surrogate vs. surrogate+2-PAM treated animals. The amount of
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seizure activity in these animals also remained unchanged after 2-PAM was administered.
These data coincide with the in vivo data, indicating no reactivation of inhibited AChE in
the brain when 2-PAM is administered, as is commonly understood in the literature
(driving the need for a centrally-acting oxime). Also, the same level of protection was
found using animals from a different supplier, providing the indication that oxime20
could be effective in the same strain of animals from different sources to equivalent
degrees. In data not shown of research conducted outside of MSU, oxime20 has also
been effective when used with live nerve agent in guinea pigs.
Collectively, the data from this research indicated that novel oxime20 was capable
of passing the blood-brain-barrier in appreciable amounts to effectively reactivate
inhibited brain AChE, and offer protection from neural damage, unlike traditionally used
oximes like 2-PAM. However, additional research needs to be done to verify the
presence of the oxime in the brain, such as using microdialysis to quantify amounts
reaching the brain. Also, the use of lipophilicity as an indicator to anticipate the
likelihood of an oxime to cross the BBB was not a very predictive tool, as many oximes
that were highly lipophilic and good reactivators of AChE in vitro failed to effectively
reactivate AChE in the brain. These data suggest that the effective in vivo oximes are
likely being transported across the brain by affinity to a transporter. However, a
transporter such as p-glycoprotein could remove oximes from the brain before they can
be efficacious (Sharom, F. J. 2006; Sharom, F. J. 2011). Further research needs to be
done to decipher the exact mechanism by which efficacious oximes, like oxime20, are
crossing the BBB to elicit an effect in the brain. Other researchers are doing similar
experiments as well, but using a different type of oxime (amidine-oxime), also with
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promising results, but using a different exposure paradigm than was used in our research
(Kalisiak, J., Ralph, E. C. et al. 2011; Kalisiak, J., Ralph, E. C. et al. 2012).
2.5

Conclusion
The nerve agent surrogates used in this research effectively mimic the live nerve

agents which they resemble. The surrogates cause neural damage (when administered in
levels to inhibit approximately 80% of brain AChE within an hour), just as nerve agents
do, and GFAP is an effective marker for documenting neurodegeneration in this rat
model where animals are treated with these surrogates. Furthermore, the surrogates
exhibit similar levels of damage in the same brain regions as kainic acid, a welldocumented positive control. The level of reactivation induced by oxime20 of surrogate
inhibited AChE in the brain (up to 35% by two hours) may be significant enough to
provide protection from long-term neural damage. Therefore, the novel chemistries used
in this study provide hope of a better treatment after exposure to OP’s, such as nerve
agents, and may alleviate lasting, deleterious health effects after exposure. It is
promising to know that use of an oxime such as oxime20 could be implemented to
augment the effectiveness of the current therapy for organophosphate poisoning and
render some protection to the brain.
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CHAPTER III
NEUROCHEMISTRY

3.1

Introduction
Neurochemical analyses in the brain provide insight on changes to

neurotransmitter systems in the brain. Perturbations to these systems may be transient, or
more persistent; however, a neurochemical evaluation of specific brain regions may
provide additional information as to how a toxicant affects the brain. Other than the
cholinergic system, several other neurotransmitter systems in the brain could be affected
by the surrogates for nerve agents that have been used in this study. Research has shown
that nerve agents impact both the serotonergic and dopaminergic systems (Fernando, J.
C., Hoskins, B. H. et al. 1984; Coudray-Lucas, C., Le Guen, A. et al. 1987; Robinson, S.
E. and Hambrecht, K. L. 1988; Fosbraey, P., Wetherell, J. R. et al. 1990; Christin, D.,
Daulon, S. et al. 2008), as well as levels of norepinephrine (el-Etri, M. M., Nickell, W. T.
et al. 1992), and the putative changes to these systems may be informative as to the
behavioral/physiological effects that are exhibited after exposure to an organophosphate
(OP), such as a nerve agent. For example, Fernando et al. demonstrated that acute, subconvulsive doses of diisopropylfluorophosphate (DFP), soman, sarin and tabun to rats
stimulated an increase in serotonergic turnover in conjunction to the overstimulation of
the cholinergic system (Fernando, J. C., Hoskins, B. H. et al. 1984). These data suggest
that the cholinergic system is not likely to be entirely responsible for the short/long term
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changes in behavior/physiology exhibited after OP poisoning. Additionally, data from
Coudray-Lucas et al. provide further evidence that the nerve agent soman has a direct
effect on the metabolism of monoamines that are unrelated to the cholinergic activity.
Here, the turnover in both serotonergic and dopaminergic systems in the brain was
increased in response to soman in rats (Coudray-Lucas, C., Le Guen, A. et al. 1987).
Consequently, the general focus of the neurochemical portion of this research evaluated
changes in serotonin, dopamine, and their metabolites to determine if our nerve agent
surrogates also modified the neurochemistry in these systems. Overall, a better
understanding of changes to this type of neurochemistry (other than cholinergic) may
provide further insight toward how a warfighter may be affected in the field of battle
when nerve agents are utilized and may help explain the etiology of other OP-induced
changes.
The same brain regions that were focused on for the neural damage experiments,
the piriform cortex and the dentate gyrus region of the hippocampus, were also evaluated
for changes in levels of monoamines. Four additional brain regions were also sampled
and analyzed to help provide a broader scope of neurochemical changes. These included
the prefrontal cortex, striatum, amygdala, and substantia nigra. The prefrontal cortex was
included to provide additional cortical neurochemical data besides the piriform cortex.
The substantia nigra and the striatum were included for neurochemical analyses to
provide data on changes to the dopaminergic nigrostriatal system. Also, research has
shown that acetylcholine (ACh), which is at excess levels during OP intoxication, can
stimulate the release of dopamine from the striatum (Giorguieff, M. F., Le Floc'h, M. L.
et al. 1976). Additionally, glutamate and kainic acid (our positive control for neural
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damage) have been shown to stimulate dopaminergic activity in the striatal region (Clow,
D. W. and Jhamandas, K. 1989). The amygdala was also included, as this area has been
shown to be a target of nerve agents and is involved in seizure activity (AroniadouAnderjaska, V., Figueiredo, T. H. et al. 2009).
3.2
3.2.1

Methods
Animals:
The initial set of animals used for these experiments were also previously tested

for GFAP expression in the piriform cortex and the dentate gyrus. Dosing of these
animals is described in the methods of Chapter Two. During the collection of the brain,
half of the brain was immediately fixed for immunohistochemistry, while the other half
was snap frozen in liquid nitrogen and saved for HPLC analyses of monoamines. These
animals were exposed to either the sarin (NIMP; 0.325mg/kg ip) or VX (NEMP;
0.4mg/kg ip) surrogate alone or in conjunction with the mesylate formulation of oxime20
(100µmoles/kg im). This experimental set of animals was sacrificed four days after
administration of surrogate and/or oxime. Additionally, an earlier time point was also
evaluated for monoamine changes, one hour after surrogate treatment, which corresponds
to the level of peak inhibition of AChE. Seizure activity commenced in the surrogate
treated animals by 20 minutes after injection and was still present at the time of sacrifice
(one hour post injection). These animals were only evaluated for the monoamine changes
resulting from the OP treatment, as no oxime was administered. These animals were also
used for an initial evaluation of oxidative stress markers (isoprostanes) in the brain at this
time point after OP administration, and will be further discussed in Chapter Four.
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3.2.2

Neurochemistry Analyses Using HPLC:
An established set of methods that have been previously published were used as a

reference to determine the levels of monoamines in punches taken from selected brain
regions (Coban, A. and Filipov, N. M. 2007), and is described below. Brains were cut in
half sagittally using a razor blade. Half of the brain was used for neurochemical
analyses, while the other half was used for immunohistochemistry (GFAP staining) or
reserved to determine levels of isoprostanes. Brain halves for HPLC or isoprostane
determination were rapidly frozen in liquid nitrogen and stored at -80°C until further
processing. The half brain used for neurochemistry was serially sliced frozen at a
thickness of 500μm using a custom designed slicing apparatus. The slicer consisted of a
aluminum block with a channel machined out to accept an indexed, adjustable sliding
block, to which the brain was attached using brain mounting medium (TissueTek). The
tick marks for adjusting the slice thickness were spaced at 125μm; therefore, the block
was indexed by four tick marks to advance the block for each new slice taken. A
pivoting arm with a razor blade attached was manually lowered to slice each brain
section. The whole apparatus was kept cold by storing it at -20°C prior to a slicing
regimen, and also by placing the slicer in a container with dry ice between times that
brains were sliced (as the punches were taken). The slices were collected on plain,
uncoated microscope slides, rapidly thawed, and re-frozen to the slide on dry ice to
achieve adherence. Punches were taken from the following selected brain regions:
prefrontal cortex, striatum, piriform cortex, dentate gyrus region of the hippocampus,
amygdala, and the substantia nigra, using the Paxinos and Watson Rat Brain Atlas
(Paxinos, G. and Watson, C. 1998) as a reference guide. The brain punches were
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individually ejected into a centrifuge tube containing 100μL of 0.2N perchloric acid to
digest the brain tissue. The samples were stored again at -80°C until all brain punches
had been collected. Samples were later thawed and kept at 4°C during processing for
HPLC. Tissue was sonicated, 10µL internal standard, 3,4-dihydroxybenzylamine
(DHBA; final concentration of 50pg/µL) was added, and then spun down for 5 minutes at
13,000g using a refrigerated centrifuge. DHBA is a precursor to epinephrine and
norepinephrine in the brain, and is commonly used as the internal standard when
determining catecholamine levels via HPLC (He, H. B., Deegan, R. J. et al. 1992). The
level of internal standard was monitored in each sample for quality control among
samples. The pellet left in the bottom of the tube was kept and used for quantification of
protein levels in each sample (Bradford assay, described below). A 40µL aliquot of the
supernatant was collected into a HPLC vial, with 20μL injected into a Waters 2695
HPLC system (Waters, Milford, MA, USA) coupled to a Waters 2465 electrochemical
detector (Waters, Milford, MA, USA).
The levels of dopamine, serotonin, and their metabolites were measured by
quantifying the area of the representative peaks in the generated chromatogram and
fitting the value to the standard curve for each of the analytes. The cocktail of analytes
included in the standard curve consisted of the following 8 components: DOPA (3,4dihydroxyphenylalanine), DOPAC (3,4-dihydroxyphenylacetic acid), NE (β-3,4trihydroxyphenethylamine; norepinephrine), 5-HIAA (5-hydroxyindoleacetic acid), HVA
(homovanillic acid), DHBA (3,4-dihydroxybenzylamine), DA (3,4dihydroxyphenethylamine; dopamine), and 5-HT (5-hydroxytryptamine; serotonin). The
following concentrations were used to generate the standard curve: 5, 12.5, 25, 50, 100,
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250, and 500pg/µL. The analytes were separated on a C18, 5µm base deactivated reversephase column (4.6µm inside diameter, 250mm in length; Supelco, Sigma) using an
isocratic flow rate of 0.75 mL/min. The mobile phase (pH 4.85) consisted of 84 mmol/L
NaH2PO4H2O, 1.15 mmol/L of octyl sodium sulfate, 0.09 mmol/L of EDTA disodium
salt, 0.25 mmol/L of triethylamine, and 17.5% methanol as an organic modifier. The
detector used was a Waters 2465 electrochemical detector (Waters, Milford, MA, USA)
with a glassy carbon flow-through detector that was set to 0.75 Volts with respect to the
Ag/AgCl reference electrode.
The neurochemistry data were normalized on a per mg protein basis after
determining the amount of protein in the tissue pellet. Supernatant was removed and
100µL of 0.5 mol/L NaOH was added to each tube and incubated for one hour at 37ºC in
a shaking water bath. Samples were diluted to a concentration of 0.1 mol/L NaOH by
adding 400µL dH20 and were then incubated for an additional 30 minutes. Samples were
diluted 1:1 with dH20 and 10µL aliquots were added to a 96 well plate. Bovine serum
albumin (BSA) was used for the standard curve (31.25, 62.5, 125, 250, and 500µg/mL)
and diluted Bradford reagent (bicinchonic acid) was added (200µL) to quantitate protein
levels. After a five minute incubation at room temperature, absorbance was read at
595nm using an automated plate reader.
3.2.3

Statistical Analyses:
One-way analysis of variance (ANOVA) was used to test differences between

treatment groups (n=3), with P<0.05 indicating significant differences (SigmaStat
Software). Tukey’s post hoc test was used when treatment groups were found to be
significantly different from one another. All data in the figures are represented as mean
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neurotransmitter/metabolite (ng/mg protein) + the standard error around the mean (SEM;
error bars). In Table 3.1 the standard deviation (SD) is also listed in addition to the SEM.
3.3

Results
Almost all of the significant differences in monoamine levels found in both

cohorts of animals (one hour post-OP treatment, and 4 days post treatment) were
confined to the serotonergic system. In the one hour experiment, no differences were
found between animals treated with dimethylsulfoxide (DMSO) and naïve controls for
any neurotransmitter/metabolite across all brain regions. Data that fell below the lowest
value on the standard curve were not analyzed, and were considered below quantitation
levels.
In the piriform cortex, the levels of norepinephrine (NE) were significantly
(p<0.05) higher in NIMP treated animals than controls (Fig. 3.1). Both serotonin (5-HT)
and its metabolite 5-HIAA were also significantly higher in the piriform cortex in NIMP
treated animals compared to controls (Fig. 3.2A and 3.2B, respectively). This same
pattern was also found in the substantia nigra and the prefrontal cortex, with both brain
regions exhibiting significantly (p<0.05) higher levels of 5-HT and 5-HIAA one hour
after treatment with the sarin surrogate, NIMP, compared to controls (Fig. 3.3A and B,
and Fig 3.4A and B, respectively). In the striatum, 5-HT trended toward being
significantly higher compared to the naïve controls in this brain region (Fig 3.5A).
However, the levels of 5-HIAA were significantly (p<0.05) elevated in the NIMP treated
animals, compared to both control groups (Fig. 3.5B). No significant differences were
found in the levels of 5-HT or its metabolite 5-HIAA in both the amygdala and the
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dentate gyrus region of the hippocampus (Fig. 3.6A and B, and Fig. 3.7A and B,
respectively) between the one hour treatment groups.
The only brain region that showed significant changes to the dopaminergic system
one hour after dosing was the striatum. The level of dopamine (Fig. 3.8A) was not
significantly different among treatment groups in this brain region; however, its
metabolite homovanillic acid (Fig. 3.8B) was significantly (p<0.05) higher in the striatum
1 hour after administration of the sarin surrogate, NIMP, compared to controls. The levels
of both DA and HVA trended (p=0.10 for both) towards an increase in NIMP treated rats
compared to controls in the amygdala (Fig. 3.9A and B, respectively).
The only significant changes found in the 4 day post-OP/oxime treated animals
were in the serotonergic system. However, there was not a strong, repeated pattern
across brain regions for this cohort. Serotonergic data for this group is summarized in
Table 3.1, with significant differences represented by lowercase letters (a vs. b) in
superscript adjacent to mean values in each column exhibiting differences between
groups. (Note: values with “ab” are not significantly different from a value labeled with
“a” or “b”).
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Table 3.1

Serotonergic activity in six brain regions of animals 4 days post treatment.
Piriform Ctx

5HT
CON

7.66
SD
SE

OxMS
SD
SE
NIMP
SD
SE
NIOX

SE
NEMP
SD
SE
NEOX
SD
SE

5HIAA
ab

5HT
a

29.16

Prefrontal Ctx

5HIAA
b

7.19

19.44

5HT
ab

5.64

Striatum

5HIAA
a

16.54

5HT
a

Den. Gyrus

5HIAA
b

3.03

10.72

5HT
a

5.16

Amygdala

5HIAA
ab

20.12

5HT
a

12.44

5HIAA
ab

22.23

ab

0.55

5.92

0.91

3.96

2.66

7.34

0.14

1.74

2.57

9.72

3.54

1.53

0.32

3.42

0.53

2.28

1.54

4.24

0.08

1.01

1.48

5.61

2.04

0.88

11.90

ab

b

15.61

a

24.90

b

31.65

5.10

a

15.16

a

a

5.26

14.49

a

5.24

ab

16.32

a

14.23

ab

24.63

ab

3.02

3.35

1.26

1.63

0.75

6.18

0.56

1.77

0.51

3.89

2.45

2.63

1.74

1.93

0.73

0.94

0.43

3.57

0.32

1.02

0.30

2.25

1.41

1.52

a

6.25

b

7.35

b

9.64

a

14.31

4.42

a

10.05

a

b

3.09

8.30

a

a

3.37

10.09

a

a

7.99

a

16.94

1.28

1.72

1.67

3.21

0.28

0.56

0.95

1.24

0.47

1.65

1.25

3.84

0.74

0.99

0.97

1.85

0.16

0.32

0.55

0.72

0.27

0.95

0.72

2.21

ab

b

a

ab

a

a

ab

a

ab

a

b

10.36

SD

Sub. Nigra

10.05

27.52

25.74

6.05

13.12

3.80

11.65

4.16

12.65

15.12

b

25.46

4.25

2.02

4.32

8.20

0.79

2.56

0.68

3.64

0.83

3.49

1.34

2.27

2.45

1.16

2.49

4.74

0.45

1.48

0.39

2.10

0.48

2.02

0.77

1.31

b

b

ab

ab

a

a

a

a

b

a

b

14.73

10.34

18.18

24.67

8.10

14.79

4.98

12.40

8.19

19.81

14.67

19.50

ab

2.71

2.75

4.50

5.47

1.58

0.55

0.65

1.88

2.35

2.39

2.82

3.18

1.56

1.59

2.60

3.16

0.91

0.32

0.37

1.08

1.36

1.38

1.63

1.83

ab

b

a

b

a

a

ab

a

ab

a

ab

9.88

15.46

24.68

33.29

4.81

11.84

3.74

13.14

4.11

13.37

11.86

24.91

ab

2.51

0.15

7.46

2.10

0.94

1.39

0.34

3.52

0.47

2.11

1.13

2.67

1.77

0.11

5.28

1.49

0.66

0.98

0.24

2.49

0.34

1.49

0.80

1.89

Serotonergic activity (serotonin, 5HT and its metabolite 5HIAA) in six brain regions
(piriform cortex, piriform ctx; substantia nigra, sub. nigra; prefrontal cortex, prefrontal
ctx; striatum; dentate gyrus, den gyrus; and amygdala) of animals 4 days post treatment.
Treatment groups (n=4-5): Control (CON), Oxime 20 mesylate (OxMS), sarin surrogate
(NIMP), NIMP+OxMS (NIOX), VX surrogate (NEMP), NEMP+OxMS (NEOX).
Significant differences between groups (p<0.05) are indicated within each column by
lowercase letters (a vs. b) in superscript adjacent to mean values in columns exhibiting
differences between groups. (Note: values with “ab” are not significantly different from
a value labeled with “a” or “b”). Bold numbers are averages in ng/mg protein, with
standard deviation (SD) and standard error (SE) located immediately below each value.
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Figure 3.1

Piriform Cortex: NE

Levels of norepinephrine (NE) were significantly (p<0.05; n=3) higher in the piriform
cortex 1 hour after administration of the sarin surrogate, NIMP (0.325mg/kg), compared
to controls. Data are represented as mean neurotransmitter (ng) per mg protein + the
SEM.
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Figure 3.2

Piriform Cortex: 5-HT and 5-HIAA

Levels of serotonin (5-HT; top fig. A) and its metabolite 5-HIAA (bottom fig. B) were
significantly (p<0.05; n=3) higher in the piriform cortex 1 hour after administration of the
sarin surrogate, NIMP (0.325mg/kg), compared to controls. Data are represented as
mean neurotransmitter/metabolite (ng) per mg protein + the SEM.
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Figure 3.3

Substantia Nigra: 5-HT and 5-HIAA

Levels of serotonin (5-HT; top fig. A) and its metabolite 5-HIAA (bottom fig. B) were
significantly (p<0.05; n=3) higher in the substantia nigra 1 hour after administration of
the sarin surrogate, NIMP (0.325mg/kg), compared to controls. Data are represented as
mean neurotransmitter/metabolite (ng) per mg protein + the SEM.
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Figure 3.4

Prefrontal Cortex: 5-HT and 5-HIAA

Levels of serotonin (5-HT; top fig. A) and its metabolite 5-HIAA (bottom fig. B) were
significantly (p<0.05; n=3) higher in the prefrontal cortex 1 hour after administration of
the sarin surrogate, NIMP (0.325mg/kg), compared to controls. Data are represented as
mean neurotransmitter/metabolite (ng) per mg protein + the SEM.
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Figure 3.5

Striatum: 5-HT and 5-HIAA

Levels of serotonin (5-HT; top fig. A) were not significantly different between groups;
however, the levels of its metabolite 5-HIAA (bottom fig. B) were significantly (p<0.05;
n=3) higher in the striatum 1 hour after administration of the sarin surrogate, NIMP
(0.325mg/kg), compared to controls. Data are represented as mean
neurotransmitter/metabolite (ng) per mg protein + the SEM.
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Figure 3.6

Amygdala: 5-HT and 5-HIAA

Levels of serotonin (5-HT; top fig. A) or of its metabolite 5-HIAA (bottom fig. B) were
not significantly (p>0.05; n=3) different across treatment groups in the amygdala 1 hour
after administration of the sarin surrogate, NIMP (0.325mg/kg), compared to controls.
Therefore, no post hoc test was performed. Data are represented as mean
neurotransmitter/metabolite (ng) per mg protein + the SEM.
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Figure 3.7

Dentate Gyrus: 5-HT and 5-HIAA

Levels of serotonin (5-HT; top fig. A) or of its metabolite 5-HIAA (bottom fig. B) were
not significantly (p>0.05; n=3) different across treatment groups in the dentate gyrus 1
hour after administration of the sarin surrogate, NIMP (0.325mg/kg), compared to
controls. Therefore, no post hoc test was performed. Data are represented as mean
neurotransmitter/metabolite (ng) per mg protein + the SEM.
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Figure 3.8

Striatum: DA and HVA

The level of dopamine (DA; top fig. A) was not significantly different among treatment
groups; however, its metabolite homovanillic acid (HVA; bottom fig. B) was
significantly (p<0.05; n=3) higher in the striatum 1 hour after administration of the sarin
surrogate, NIMP (0.325mg/kg), compared to controls. Data are represented as mean
neurotransmitter/metabolite (ng) per mg protein + the SEM.
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Figure 3.9

Amygdala: DA and HVA

Levels of dopamine (DA; top fig. A) or of its metabolite HVA (bottom fig. B) were not
significantly (p=0.10; n=3) different across treatment groups in the amygdala 1 hour after
administration of the sarin surrogate, NIMP (0.325mg/kg), compared to controls.
Therefore, no post hoc test was performed; however, NIMP treated rats trended to be
higher than controls in this brain region for both DA and HVA. Data are represented as
mean neurotransmitter/metabolite (ng) per mg protein + the SEM.
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3.4

Discussion
The OP nerve agent surrogates seem to have the greatest impact on the

serotonergic system, as elicited strongly in the one hour post-OP treated animals, and also
to a more subtle degree in the 4 day post treatment animals. One hour after
administration of the sarin surrogate, serotonergic activity was increased in several brain
regions (piriform cortex, substantia nigra, prefrontal cortex, and striatum), as evidenced
by higher levels of both the neurotransmitter (5-HT) and metabolite (5-HIAA). These
data indicate that the OP (NIMP) induces greater production and use of 5-HT in these
brain regions, hence more serotonergic turnover. Additionally, these data are consistent
with other studies showing acute, increased serotonergic turnover in the brain after
injection with sub-lethal amounts of other nerve agents or other OPs (paraoxon, DFP,
soman, sarin, and tabun), exhibiting signs of seizures (Prioux-Guyonneau, M., CoudrayLucas, C. et al. 1982; Fernando, J. C., Hoskins, B. H. et al. 1984). By four days after
treatment, the pattern is less consistent. However, at four days, all of the treatment
groups have significantly less 5-HIAA compared to control animals in the piriform
cortex, indicating a persistent alteration in serotonergic activity. These data parallel the
neural damage demonstrated by a consistent increase in GFAP expression in this brain
region in our research (Chapter Two). The piriform cortex is known to be a target area of
nerve agent induced damage (Chapman, S., Kadar, T. et al. 2006; Myhrer, T., Enger, S. et
al. 2007; Myhrer, T., Enger, S. et al. 2010). Epileptic-type seizures have also been found
to increase brain levels of serotonin and dopamine in rats treated with d-amphetamine
(Tor-Agbidye, J., Yamamoto, B. et al. 2001). Interestingly, in a study done by Yan et al.
using microdialysis to administer serotonin to convulsing, epilepsy-prone rats, 5-HT
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demonstrated an anticonvulsant effect in these animals (Yan, Q. S., Jobe, P. C. et al.
1995). These data suggest that upon the onset of seizures, animals may produce and use
more serotonin in an effort to combat the seizure, although the mechanism is not clear.
Current research has indicated that several of the serotonin receptors (ex. 5-HT3/7) may
be linked to the susceptibility of epileptic-type seizures (Pericic, D. and Svob Strac, D.
2007; Gholipour, T., Ghasemi, M. et al. 2010). Higher serotonergic turnover may also
just be a consequence of the seizure activity.
The acute (one hour) changes of increased serotonergic activity are located in
brain regions that are likely to be involved in the seizure activity induced by the nerve
agent surrogate (NIMP), suggesting that the seizures are likely propagating the increased
production of 5-HT and the generation of more 5-HIAA. In other words, the increased
serotonergic activity is most likely a product of the seizure, itself, in conjunction to the
already elevated levels of acetylcholine (as evidenced by the inhibition of the AChE one
hour after NIMP; Chapter Two), linking the overstimulation of the cholinergic system to
the increases in the serotonergic system in seizure impacted areas (Fosbraey, P.,
Wetherell, J. R. et al. 1990); however, it is still unclear if the two systems are directly
affecting one another. The increases in serotonergic activity in the one hour NIMP
treated animals may be a result of the brain coping with the seizures. The consistent
lower levels of 5-HIAA in the piriform cortex in the 4 day treated animals may be due to
this region being “burnt out” due to impending damage. Additionally, the increase of NE
in the piriform cortex at one hour post NIMP injection is also likely a product of the
increased stress to this region during the seizure activity, and may be involved in the
induction and maintenance of the seizures. Similar results were also found by el-Etri et
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al., where after exposure to soman in rats, an abrupt change in NE was followed by
slower, more progressive changes in the serotonergic and dopaminergic systems, which
also showed an increase in the turnover of both systems in convulsive animals (el-Etri,
M. M., Nickell, W. T. et al. 1992).
3.5

Conclusion
Overall, the data gathered here suggests that the evaluation of brain monoamines

can be a useful tool to evaluate the impact of nerve agents or other OPs. However, the
acute (one hour) changes to monoamines, particularly 5-HT and its metabolite 5-HIAA,
are most likely a result of seizure activity in the brain. If these short-term increases in
serotonergic activity were dampened after administration of oxime, this may be an
additional indicator of oxime effectiveness. The reduction in seizure activity observed in
surrogate treated rats after the administration of oxime20 should also be paralleled with a
dampened response to the increase in serotonergic activity caused by the surrogate. A
short-term evaluation of brain monoamines in OP/oxime treated animals would need to
be done to address this idea. Animals would need to be sacrificed between 30 minutes to
2 hours after the administration of oxime20, as this is the time frame when seizure
attenuation is observed, and would parallel the AChE inhibition data. Documentation of
attenuation of seizure behavior (which has already been observed) is likely to show the
same endpoint, an early effect of oxime20. No consistent effect of oxime20 was found
on monoaminergic changes in the brain 4 days after treatment with the OP/oxime.
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CHAPTER IV
OXIDATIVE STRESS: ISOPROSTANES

4.1

Introduction
Evidence exists that acute exposure to OPs will generate reactive oxygen species

(ROS) as well as excessive stimulation to glutamatergic neurons (Wade, J. V., Samson,
F. E. et al. 1987; Lallement, G., Denoyer, M. et al. 1992; Milatovic, D., Gupta, R. C. et
al. 2006). The overstimulation of both the cholinergic and glutamatergic neuronal
systems in conjunction with the generation of ROS may lead to detrimental neuronal
damage. Two biomarkers to evaluate ROS in the brain are F2-isoprostanes (F2-isoPs) and
F4-neuroprostanes (F4-NeuroPs), which are oxidative damage products of arachidonic
acid (AA) and docosahexaenoic acid (DHA), respectively (Montine, T. J., Quinn, J. F. et
al. 2002). The F2-isoPs are found ubiquitously in the brain, while the F4-NeuroPs are
localized to neuronal membranes. These markers have been successfully used to evaluate
oxidative damage due to exposure to OPs, as is evidenced by the work of Milatovic and
Aschner at Vanderbilt University using diisopropylphosphorofluoridate (DFP) in a
Sprague Dawley rat model (Zaja-Milatovic, S., Gupta, R. C. et al. 2009). In their
experiments, elevation of both F2-isoPs and F4-NeuroPs began by 30 minutes after a
single injection (1.25 mg/kg, sc) of DFP, with peak levels reached at 60 minutes, and
were still significantly elevated at 2 hours, but returned to control levels by 6 hours.
Brain AChE was also inhibited by 90% at 30 minutes, and was sustained at 60 minutes.
77

By 2 hours, AChE was still inhibited by 86%, with levels dropping to 83% by 6 hours.
Dendritic damage to pyramidal neurons in the CA1 region of the hippocampus was also
found in animals sacrificed 1 hour post-injection with the OP. Pretreatment with
antioxidants [vitamin E (α-tocopherol), N-tert-butyl-α-phenynitrone (PBN), and
memantine HCl (MEM)] were found to protect from the oxidative damage. The
surrogates that have been developed and utilized in our research at MSU are
hypothesized to also evoke oxidative stress in the brain, just as DFP has been shown to
do. The dosages that we use for our in vivo experiments using nerve agent surrogates
(NIMP and NEMP) cause the same degree of inhibition of AChE and also display very
similar kinetics (peak inhibition about 1 hour post injection) as the DFP experiments
done at Vanderbilt (Chambers, J. E., Chambers, H. W. et al. 2012; Meek, E. C.,
Chambers, H. W. et al. 2012).
This chapter describes the method development that has been done to characterize
oxidative damage induced by the novel nerve agent surrogate NIMP by evaluating the
levels F2-isoPs in the brain. The ultimate plan was to characterize both the F2-isoPs and
the F4-NeuroPs in brain tissue exposed to the nerve agent surrogates; however, it proved
to be extremely difficult to secure a standard to use for analysis of the F4-NeuroPs.
Consequently, this chapter describes only the method development performed for the F2isoPs. The methodology used by the researchers at Vanderbilt University utilizes gas
chromatography coupled to a mass spectrometer (GCMS) following an extensive
derivatization process for the quantification of the isoprostanes in brain tissue. The
research done thus far at MSU has followed the same basic methodology as described by
the Vanderbilt team (Milatovic, D. and Aschner, M. 2009; Milatovic, D., Montine, T. J.
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et al. 2011); however, ultra high performance liquid chromatography coupled to a mass
spectrometer (UPLC/MS) was used and no derivatization was necessary. During the
method development, isoprostanes were found in measurable amounts in both control and
NIMP treated samples; consequently, these samples guided further method development
to enhance the recovery of the isoprostanes during the extraction process. After we were
confident that we had fully optimized our extraction process, the one hour post NIMP
administration animals that were used for HPLC analyses of monoamines were analyzed
for isoprostanes. Two additional animals of each group were also treated and included in
the dataset as an additional replication.
There is evidence that dimethylsulfoxide (DMSO) can have an antioxidant effect
(Sanmartin-Suarez, C., Soto-Otero, R. et al. 2011); consequently, a DMSO control group
of animals was included for comparison to the NIMP treated animals (as DMSO is the
vehicle for delivery of the surrogate via ip injection). In these same animals, no effects
were found on neurochemistry resulting from exposure to DMSO compared to naïve
control animals (Chapter 3). These initial experiments were conducted by evaluating the
one hour post OP (NIMP) treatment, which corresponds to the time of peak isoprostane
levels found by the Aschner group using DFP. This is also the time of peak AChE
inhibition, both by the surrogates used in this research (Chapter Two), and by DFP used
by Zaja-Milatovic et al. in their experiments (Zaja-Milatovic, S., Gupta, R. C. et al.
2009). In our experiment, three animals were used for each of the following treatment
groups: naïve control, DMSO control, and NIMP, with two additional animals for each
group added later (five total replications).
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If elevated levels of isoprostanes were found in NIMP treated animals, later
experiments could be conducted to incorporate oxime20 (the oxime used with GFAP and
neurochemistry experiments; and most effective reactivator of AChE), as the oxime
would be given to some of the animals alone and in conjunction with the surrogate to test
its effect on the levels of isoprostanes. The overall hypothesis was that NIMP should
induce oxidative stress, like DFP has been found to do, and if so, administration of
oxime20 may have the potential to reduce the generation of reactive oxygen species.
Additionally, administration of an antioxidant like vitamin E (α-tocopherol) may serve as
another tool to potentially reduce the detrimental effects of OPs like nerve agents.
4.2
4.2.1

Methods
Dosing of Animals and Brain Collection:
Rats were given a single ip injection of the selected nerve agent surrogate (NIMP

in DMSO, 0.325mg/kg; injected at 1ml/kg body weight) or an equivalent dosage of
DMSO only (n=5 for each group). Animals were monitored for seizure activity and then
sacrificed one hour post treatment with OP or DMSO vehicle. Five additional rats were
used as naïve controls. Brains were rapidly dissected from the skull, cut in half sagittally,
flash frozen in liquid nitrogen, and stored at -80°C until further processing.
4.2.2

Isoprostane Extraction from Brain Tissue:
The methodology that has been developed and used by Dr. Ross and Lee Mangum

here at MSU using LCMS for tissue types other than brain was used for the method
development of the extraction of isoprostanes from brain tissue. Much of their method
development was based on the methods described by Masoodi and Nicolaou of which
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brain is noted as a tissue that should work with their methods (Masoodi, M. and
Nicolaou, A. 2006).
Moreover, the following description is a summary of the final version of the
protocol that was used for the experiment described above. Brain tissue (500mg) was
homogenized in 20ml of ice-cold Folch solution (chloroform:methanol, 2:1, vol:vol)
containing 0.005% BHT (butylated hydroxytoluene; free radical scavenging agent) and
the tube was then flushed to remove air using a nitrogen stream. The tube was capped
and then incubated for 20 minutes at room temperature (RT; 22ºC), shaking periodically
for a few seconds throughout the incubation period. Lipid extracts were mixed with 4ml
of NaCl solution (0.9%, wt/vol in ultrapure water), sonicated at RT, transferred to 15ml
glass tubes, and the aqueous/organic layers were then separated by centrifugation at 300 x
g for 5 min at RT. The upper, aqueous layer was pipetted off and discarded, and the
lower organic layer was transferred to a clean 15ml glass tube, while avoiding the
semisolid intermediate protein layer, and the organic phase was evaporated to dryness
under a nitrogen stream. The lipid sample was then dissolved in 4ml methanol
containing 0.005% BHT, vortexed, and then 4ml of aqueous KOH (15%) was added.
The sample was vortexed, purged with nitrogen, capped and then incubated for 30 min at
37°C in a water bath. The mixture was then acidified to pH3 by adding 1N HCl, and then
diluted to 80ml by adding pH3 water (separated into two, 50ml tubes). Next, 2ng (40μl)
of internal standard was added, [2H4]-8-iso-PGF2α, and the sample was vortexed. A C-18
Sep-Pak cartridge was conditioned using 7ml methanol and 7ml pH3 water. The
acidified lipid mixture was then pulled through the pre-treated column under light
vacuum. The column was then sequentially washed with 10ml pH3 water and 10ml
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hexane. The F2-IsoPs were then eluted by washing the column with 10ml ethyl acetate
into a glass scintillation vial. Next, a silica column was equilibrated with 5ml ethyl
acetate. The sample was applied to the silica column under light vacuum. The column
was then rinsed with 5ml ethyl acetate, and the sample was eluted via addition of 5ml of
1:1 ethyl acetate:methanol, and dried again under nitrogen. The sample was resuspended in 100μl of water/methanol (1:1), centrifuged for 1 min, transferred to an
Ultrafree-MC spin filter, centrifuged for 2 min at 16,000g, and then transferred to a glass
vial with insert and then loaded onto the LCMS. A volume of 10μl of sample was
injected into the system for analysis.
The F2-isoprostanes were quantified using a Waters Acquity Ultra Performance
Liquid Chromatograph (UPLC) coupled to a Thermo Scientific TSQ Quantum Access
MAX triple quadrupole mass spectrometer using the method validated by Masoodi and
Nicolaou (Masoodi, M. and Nicolaou, A. 2006). Chromatography was performed on a
BEH C18 2.1x50mm column with water/methanol + 0.1% acetic acid as the mobile phase.
UPLC/ESI-MS/MS analysis of a selected 15-series (side chain –OH is on carbon 15) F2isoprostane, 8-iso-PGF2α, by single reaction monitoring (SRM), was accomplished by
monitoring the transition m/z 353→193. The internal standard [2H4]-8-iso-PGF2α was
monitored by the transition m/z 357→197.
4.2.3

Statistical Analyses:
One-way analysis of variance (ANOVA) was used to test differences between

treatment groups, with P<0.05 indicating significant differences (SigmaStat Software).
Tukey’s post hoc test was used when treatment groups were found to be significantly
different from one another.
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4.3

Results
Levels of the F2-isoprostane, 8-iso-PGF2α, in the brain one hour after

administration of the sarin surrogate, NIMP (0.325mg/kg), trended to be significantly
lower than naïve controls (P<0.1). However, the DMSO treated animals had significantly
lower levels of this isoprostane compared to the controls (P<0.05). No significant
difference was found between the DMSO treated group and the NIMP treated group
(note: DMSO was the vehicle)(Fig. 4.1).

Figure 4.1

8-iso-PGF2α: 1 Hour Treatment

Levels of the F2-isoprostane, 8-iso-PGF2α, in the brain one hour after administration of
the sarin surrogate, NIMP (0.325mg/kg) trended to be significantly lower than naïve
controls (P<0.1; n=5). The DMSO treated animals, however, had significantly lower
levels of this isoprostane compared to the controls (P<0.05; n=5). No significant
difference was found between the DMSO treated group vs. the NIMP treated group (note:
DMSO was the vehicle). Data are represented as mean sample areas + the SEM.
4.4

Discussion
The F2-isoPs in the brain tissue were detectable after several rounds of

optimization of the methodology. Additional peaks of substantial size were also
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observed in the chromatography results for the samples, which differed in size among the
samples. While it would have been ideal to have the standard for the F4-neuroPs, they are
not commercially available and are difficult to secure from the very limited number of
researchers that use them. This method of characterizing F2-isoPs and F4-neuroPs (if a
standard could be obtained) would provide unique data to additionally characterize the
effects of OPs, like the nerve agent surrogates used in this research.
The levels of 8-iso-PGF2α in the brain were lower in animals that were treated
with DMSO only or NIMP (in DMSO vehicle) compared to the naïve controls. These
results were not anticipated. These data suggest a potential antioxidant effect in the brain
by DMSO in these samples, occurring as early as one hour post treatment, and these
results also support other research showing antioxidant properties of DMSO (SanmartinSuarez, C., Soto-Otero, R. et al. 2011). Additional studies would need to be done to
further elucidate these results. The administration of DFP by the researchers at
Vanderbilt University for their isoprostane experiments was based on previous work
(Zivin, M., Milatovic, D. et al. 1999), and the OP surrogate was given subcutaneously in
0.9% saline. An experiment administering a different vehicle (possibly saline) for the
surrogate would provide more insight toward how isoprostane levels could be altered.
4.5

Conclusion
The methodology for extracting and analyzing F2-isoprostanes, particularly 8-iso-

PGF2α, in the brain outlined in this chapter seems adequate; however, the levels detected
were relatively low. When standards for the F4-neuroprostanes become commercially
available (this research is becoming more popular), additional experiments would be
informative about the impact of the nerve agent surrogates in the brain. However, these
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preliminary data shown here question the use of DMSO as a vehicle for the surrogates
when studying the oxidative effects of these chemicals, as DMSO may mask the effects
of the surrogates.
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CHAPTER V
CONCLUSION

While the risk of exposure to OPs, such as nerve agents, exists for many
individuals throughout the world, a fully protective treatment upon exposure does not. A
lack of protection still remains for the brain. Overall, the results of our research have
pointed toward a better understanding of how the brain can be altered by OPs and has
discovered a novel oxime that may someday contribute to a better treatment for OP
poisoning.
The nerve agent surrogates used in this research effectively mimic the live nerve
agents which they resemble. When administered at levels that induce maximal signs of
OP poisoning without causing lethality, the surrogates cause neural damage, just as nerve
agents do. Kainic acid, a documented positive control for induction of seizures and
expression of GFAP, elicited similar levels of seizure activity and damage in the same
brain regions as the surrogates used in this research did, and all of these chemicals
showed the potential to induce neurodegeneration. The amount of reactivation created by
oxime20 of surrogate inhibited AChE in the brain (up to 35% by two hours) may be
significant enough to provide protection from long-term neural damage. Consequently,
the novel chemistries used in this study provide hope of a better treatment after exposure
to OP’s, such as nerve agents, and may alleviate lasting, deleterious health effects after
exposure. It is promising to know that use of an AChE reactivator such as oxime20 could
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be implemented to supplement the effectiveness of the current therapy for
organophosphate poisoning and provide some protection to the brain.
The evaluation of brain monoamines can also be a useful tool to evaluate the
impact of nerve agents or other OPs. The bulk of the changes to monoamines in this
research were found in the serotonergic system of animals treated with NIMP (one hour
post administration) and are most likely due to seizure activity in the brain. If these
short-term increases in serotonergic activity were dampened after administration of
oxime, this may be an additional indicator of oxime effectiveness. The attenuation of
seizure activity observed in surrogate treated rats after the administration of oxime20
should also be paralleled with a dampened response to the increase in serotonergic
activity caused by the surrogate. A short-term (30 minutes to 2 hours after the
administration of oxime20) evaluation of brain monoamines in OP/oxime treated animals
would need to be done to address this idea. However, the already observed attenuation of
seizure behavior will likely show the same endpoint, an early effect of oxime20 in the
brain.
The methods that were developed to extract and analyze F2-isoprostanes,
particularly 8-iso-PGF2α, in the brain were consistent between replications; however, the
level of detection was still relatively low. Hopefully, standards for the F4-neuroprostanes
will become commercially available sometime soon, as additional experiments would be
informative about the impact of the nerve agent surrogates in the brain. Additionally, the
first sets of isoprostane experiments performed suggest that DMSO may not be the ideal
vehicle for the OP surrogates when evaluating the oxidative effects of these chemicals, as
DMSO could exhibit antioxidant properties that could hide the effects of the surrogates.
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Future directions for this general research could include an evaluation of
inflammatory markers (ex. TNFα, IL-1α, IL-1β) both in the periphery and in the brain
after exposure to the nerve agent surrogates. The Luminex™ multiplex immunoassay
technology could be utilized to quickly screen for an array of these types of markers. If
changes were found due to surrogate exposure, additional tests could be done in
conjunction with some of the novel oximes, particularly oxime20. Also, the blood-brainbarrier had to have been crossed by oxime20 in this research. More research could also
be done to discover the route by which the oxime was able to penetrate the brain. Also,
concrete verification of the presence of the oxime in the brain would further validate its
effectiveness at this location. Micro-dialysis could be used to look for the oxime in the
CSF within the brain, and HPLC methodology should be able to detect the chemical.
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APPENDIX A
OXIMES
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Table A.1

Structures of the novel oximes that were created and used in this research.

Oxime

na

Rb

Oxime 001
Oxime 006
Oxime 013

4
4
3

4-Cl3-CHCH=CHCH-4
3-CHCH=CHCH-4

Oxime 020

4

4-Ph-CH2-O-

Oxime 021

4

2,5-Cl2-

Oxime 029

4

3,4-Cl2-

Oxime 030

3

2,4,6-Cl3-

Oxime 032

5

3-O-C(:O)CH=C(CH3)-4

Oxime 033

3

3,4-Cl2-

Oxime 036

4

2,6-([CH3] 2 CH)2-

Oxime 037

4

3-CH3-4-Cl-

Oxime 038

4

2,6-Cl 2-4-O2N-

Oxime 039

4

2,4,6-Cl3-

Oxime 045

5

4-Br-

Oxime 047

5

2,3,5-(CH3)3-

Oxime 048
5
3-CHCH=CHCH-4
Number of C’s in alkyl chain (n of “Experimental Oxime” in Figure 2).
b
Substitutions on the phenoxy moiety (R of “Experimental Oxime” in Figure 2).
a
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Figure A.1

Organophosphate Surrogates

The organophosphate surrogates used in this study include, 4-nitrophenyl isopropyl
methylphosphonate (NIMP, a sarin surrogate) and 4-nitrophenyl ethyl
methylphosphonate (NEMP, a VX surrogate). The most efficacious oxime, Oxime 20,
was tested in two formulations, bromide (Ox20) and mesylate (OxMS) salts.
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Figure A.2

Novel Oximes

The novel oximes that were created in this research are based on the generic structure
shown above. The various R-groups and numbers of methylene groups (n) are depicted
in appendix table 1 for each of the novel oximes described. In addition, the structures are
shown for two of the traditionally used oximes (TMB-4 and 2-PAM) for reactivation of
organophosphate inhibited acetylcholinesterase. Novel oximes were compared to these
traditional oximes.

94

